HEK5, HEK7, HEK8, HEK11, NEW EPH-LIKE RECEPTOR PROTEIN TYROSINE KINASES

Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.

Description: HEK5, HEK7, HEK8, HEKll, new EPH-Uke receptor protein tyroslne klπases Field of the Invention The invention relates generally to receptor protein tyrosine inases (PTKs) and particularly to novel Eph-like receptor PTKs, to fragments and analogs thereof, and to nucleic acids encoding same. The present invention also relates to methods of producing and using such receptors. Background of the Invention Receptor PTKs are a structurally related family of proteins that mediate the response of cells to extracellular signals (Ullrich et al. Cell £1, 203-212 (1990)) . These receptors are characterized by three major functional domains: an intracellular region containing the sequences responsible for catalytic activity, a single hydrophobic membrane-spanning domain, and a glycosylated extracellular region whose structure determines ligand binding specificity. Signal transduction is initiated by the binding of growth or differentiation factors to the extracellular domain of their cognate receptors. Ligand binding facilitates dimerization of the receptor which can induce receptor autophosphorylation. Both soluble and membrane- associated protein ligands have been shown to function in this manner. This process is the initial step in a cascade of interactions involving the phosphorylation of a variety of cytoplasmic substrates and culminating in a biological response by the cell. The best characterized response to tyrosine kinase receptor activation is cell growth. However, analysis of the role of some growth factors in vivo suggests that differentiation or cell survival might also be mediated by tyrosine kinase receptor/ligand interactions. Receptor PTKs have been grouped into fairly well-defined families on the basis of both sequence homology and shared structural motifs. The amino acid sequence of the portion of the intracellular domain responsible for the catalytic activity is well conserved among all tyrosine kinases and even more closely matched within a receptor sub-family. Comparisons of this portion of the amino acid sequence have been used to construct phylogenetic trees depicting the relatedness of family members to each other and to the tyrosine kinases as a whole (Hanks and Quinn, Methods Enzymol. 200, 38-62 (1991)). This sequence conservation has also been exploited in order to isolate new tyrosine kinases using the polymerase chain reaction (PCR) (Wilks, Proc. Natl. Acad. Sci. USA , 1603-1607 (1989)). Oligonucleotides based on the highly conserved catalytic domain of PTKs can be used as PCR primers to amplify related sequences present in the template. These fragments can then be used as probes for isolation of the corresponding full-length receptor clones from cDNA libraries. Anti-phosphotyrosine antibodies have also been used to identify PTK cDNA clones in phage expression libraries (Lindberg and Pasquale, Methods Enzymol. 2 HL, 557-564 (1991)). These strategies have been used by a number of investigators to identify an ever-increasing number of protein tyrosine kinase receptors. There are now 51 distinct PTK receptor genes that have been published and divided into 14 sub-families One such sub-family is the EPH-like receptors. The prototype member, EPH, was isolated by Hirai et.al. (Science 238. 1717-1720 (1987)) using low stringency hybridization to a probe derived from the viral oncogene v-fps. EPH-like receptors have been implicated in cell growth based in part on studies which show that overexpression of the gene in NIH3T3 cells causes focus formation in soft agar and tumors in nude mice (Maru et al. Oncogene 5_, 199-204 (1990)). Other members of the EPH sub-family which have been identified include the following: ECK (Lindberg et al. Mol. Cell. Biol. IH, 6316-6324 (1990)) Elk (Lhotak et al. Mol. Cell. Biol. ϋ, 2496- 2502 (1991)) Ceks 4,5,6,7,8,9, and 10 (Pasquale, Cell Regulation Z, 523-534 (1991); Sajjadi et al. The New Biologist 2., 769-778 (1991); Sajjadi and Pasquale Oncogene £, 1807-1813 (1993)) HEK2 (Bohme et al. Oncogene , 2857-2862 (1993)) Eek, Erk (Chan and Watt, Oncogene £, 1057-1061 (1991)) Ehkl, Ehk2 (Maisonpierre et al. Oncogene £, 3277-3288 (1993)) Homologs for some of these receptors have been identified in other species (Wicks et al. Proc. Natl. Acad. Sci. USA M, 1611-1615 (1992)); Gilardi- Hebenstreit et al. Oncogene 1, 2499-2506 (1992)). The • expression patterns and developmental profiles of several family members suggest that these receptors and their ligands are important for the proliferation, differentiation and maintenance of a variety of tissues (Nieto et al. Development 116, 1137-1150 (1992)). Structurally, EPH sub-family members are characterized by an Ig-like loop, a cysteine rich region, and two fibronectin-type repeats in their extracellular domains. The amino acid sequences of the catalytic domains are more closely related to the SRC sub-family of cytoplasmic PTKs than to any of the receptor PTKs. Among the catalytic domains of receptor PTKs, the EPH sub-family is most similar in amino acid sequence to the epidermal growth factor receptor sub-family. It is an object of the invention to identify novel receptors belonging to the EPH sub-family. A directed PCR approach has been used to identify five human EPH-like receptors from a human fetal brain cDNA library. These receptors are designated HEK4, HEK5, HEK7, HEK8, and HEKll. The relationship of these receptors to previously identified EPH-like receptors is as follows: HEK4 is the human homolog of Cek4 (chicken) and Mek4 (mouse) and is identical to HEK (Boyd et al. J. Biol. Chem. 267. 3262-3267 (1992); Wicks et al., 1992) which was previously isolated from a human lymphoid tumor cell line. HEK5 is the human homolog of Cek5, a full- length eph-like receptor clone from chicken. A portion of the HEK5 sequence was previously disclosed as ERK, a human clone encoding about sixty amino acids (Chan and Watt, 1991) HEK7 is the human homolog of Cek7 isolated from chicken. HEK8 is the human homolog of Cek8 a full- length clone from chicken and Sek, a full-length clone from mouse. (Nieto et al. , 1992; Sajjadi et al. , 1991) HEKll does not have a known non-human homolog. With the addition of the new members HEK5, HEK7, HEK8 and HEKll and the report of a PCR fragment encoding an eph-like receptor (Lai & Lemke Neuron £, 691-704 (1991)), a total of twelve distinct sequences that represent EPH-like receptors have been published, making it the largest known sub-family of PTKs. It is a further object of the invention to generate soluble EPH-like receptors and antibodies to EPH-like receptors. Soluble receptors and antibodies are useful for modulating EPH-like receptor activation. Summary of the Invention The present invention provides novel EPH-like receptor protein tyrosine kinases. More particularly, the invention provides isolated nucleic acids encoding four novel members of the sub-family of EPH-like receptor PTKs which are referred to collectively as HEKs (human-eph like kinases) . Also encompassed are nucleic acids which hybridize under stringent conditions to EPH-like receptor nucleic acids. Expression vectors and host cells for the production of receptor polypeptides and methods of producing receptors are also provided. Isolated polypeptides having amino acid sequences of EPH-like receptors are also provided, as are fragments and analogs thereof. Antibodies specifically binding the polypeptides of the invention are included. Also comprehended by the invention are methods of modulating the endogenous activity of an EPH-like receptor and methods for identifying receptor ligands. Description of the Figures Figure 1 shows the nucleotide and predicted amino acid sequence of the HEK5 receptor. Figure 2 shows the nucleotide and predicted amino acid sequence of the HEK7 receptor.- Figure 3 shows the nucleotide and predicted amino acid sequence of the HEK8 receptor. - 6 - Figure 4 shows the nucleotide and predicted amino acid sequence of the HEKll receptor. Figure 5 shows the comparison of the amino acid sequences of the human EPH receptor sub-family. The multiple sequence alignment was done using the LineUp program included in the Genetics Computer Group sequence analysis software package (Genetics Computer Group, (1991), Program Manual for the GCG Package, Version 7, April 1991, Madison, Wisconsin, USA 53711) . Dots indicate spaces introduced in order to optimize alignment. The predicted transmembrane domains and signal sequences of each receptor are indicated by underlining and italics, respectively. Cysteine residues conserved throughout the sub-family are indicated with asterisks. Arrows indicate the tyrosine kinase catalytic domain. Amino acid sequences of EPH, ECK and HEK2 were taken from the appropriate literature references. Figure 6 shows the molecular phylogeny of the EPH sub¬ family of receptor protein tyrosine kinases. Catalytic domain sequences were analyzed as described by Hanks and Quinn, 1991. The scale bar represents an arbitrary evolutionary difference unit. The EPH branch, which has been shown with a discontinuity for the sake of compactness, is 23.5 units in length. Figures 7-11 show Northern blot analyses of the tissue distribution of the HEK receptors. Receptor cDNA probes, labeled with 32p^ we re hybridized to either 2 μg of poly A + RNA from human tissues (panel A, Clontech) or 10 μg of total RNA from rat tissues (panel B) . Sizes of the transcripts were determined by comparison with RNA molecular weight markers (Bethesda Research Labs, - 7 - Gaithersburg, MD) . Figure 7, HEK4; Figure 8, HEK5; Figure 9, HEK7; Figure 10; HEK8; Figure 11; HEK 11. Detailed Description of the Invention The present invention relates to novel EPH-like receptor protein tyrosine kinases. More particularly, the invention relates to isolated nucleic acids encoding four novel members of the sub-family of EPH-like receptor PTKs. These four members are designated herein as HEK (human eph-like kinases) . Nucleic acids encoding HEK receptors were identified in a human fetal brain cDNA library using oligonucleotide probes to conserved regions of receptor PTKs and EPH- like receptor PTKs. The predicted amino acid sequences of three HEK receptors had extensive homology in the catalytic domain to previously identified EPH-like receptors Cek5, Cek7 and Cek8 isolated from chicken and, accordingly, are designated HEK5, HEK7 and HEK8. The predicted amino acid sequence of the fourth HEK receptor revealed that it was not a homolog of any previously identified EPH-like receptor. It is designated HEKll. It is understood that the term "HEKs" comprises HEK5, HEK7, HEK8 and HEKll as well as analogs, variants, and mutants thereof which fall within the scope of the invention. The invention encompasses isolated nucleic acids selected from the group consisting of: (a) the nucleic acids set forth in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16 and their complementary strands; (b) a nucleic acid hybridizing to the coding regions of the nucleic acids in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16 under stringent conditions; and (c) a nucleic acid of (b) which, but for the degeneracy of the genetic code, would hybridize to the coding regions of the nucleic acids in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. The nucleic acids of the invention preferably hybridize to HEK5, HEK7, HEK8, or HEKll coding regions under conditions allowing up to about 5% nucleotide mismatch based upon observed nucleic acid identities among known human or nonhuman EPH-like receptors. An example of such a condition is hybridization at 60° in 1M Na + followed by washing at 60° in 0.2XSSC. Other hybridization conditions may be ascertained by one skilled in the art which allow base pairing with similar levels of mismatch. In a preferred embodiment, the isolated nucleic acids encode polypeptides having the amino acid sequences of HEK5, HEK7, HEK8 or HEKll. A nucleic acid includes cDNA, genomic DNA, synthetic DNA or RNA. Nucleic acids of this invention may encode full-length receptor polypeptides having an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic domain, or may encode fragments such as extracellular domains which are produced in a soluble, secreted form. Nucleic acid constructs which produce soluble HEK receptors are described in Example 3. Polypeptides and fragments encoded by the nucleic acids have at least one of the biological activities of an EPH-like receptor protein tyrosine kinase, such as the ability to bind ligand. The invention also encompasses nucleic acids encoding chimeric proteins wherein said proteins comprise part of the amino acid sequence of a HEK receptor linked to an amino acid sequence from a heterologous protein. One example of such a chimeric protein is an extracellular domain of a HEK receptor fused to a heterologous receptor cytoplasmic domain. Example 5 describes the construction and expression of a chimeric receptor comprising the HEK8 extracellular domain with the trkB cytoplasmic domain and a second chimeric receptor comprising the HEKll extracellular domain with the trkB cytoplasmic domain. HEK receptors may also be fused to other functional protein domains, such as an Ig domain which acts as an antibody recognition site. The nucleic acids of the present invention may be linked to heterologous nucleic acids which provide expression of receptor PTKs. Such heterologous nucleic acids include biologically functional plasmids or viral vectors which provide genetic elements for transcription, translation, amplification, secretion, etc. One example of an expression vector suitable for producing EPH-like receptors of the present invention is pDSRtx which is described in Example 3. It is understood that other vectors are also suitable for expression of EPH-like receptors in mammalian, yeast, insect or bacterial cells. In addition, in vivo expression of nucleic acids encoding EPH-like receptor PTKs is also encompassed. For example, tissue-specific expression of EPH-like receptors in transgenic animals may be readily effected using vectors which are functional in selected tissues. Host cells for the expression of EPH-like receptor PTKs will preferably be established mammalian cell lines, such as Chinese Hamster Ovary (CHO) cells or NIH 3T3 cells, although other cell lines suitable for expression of mammalian genes are readily available and may also be used. Such host cells are transformed or transfected with nucleic acid constructs suitable for expression of an EPH-like receptor. Transformed or transfected host cells may be used to produce suitable quantities of receptor for diagnostic or therapeutic uses and to effect targeted expression of EPH-like receptors in selected adult tissues, such as brain, kidney, and liver, or in embryonic or rapidly dividing tissues. The present invention provides purified and isolated polypeptides having at least one of the biological properties of an EPH-like receptor (e.g. ligand binding, signal transduction) . The isolated polypeptides will preferably have an amino acid sequence as shown in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16. Polypeptides of this invention may be full-length polypeptides having an extracellular domain, a transmembrane domain, and a cytoplasmic domain, or may be fragments thereof, e.g., those having only an extracellular domain or a portion thereof. It will be understood that the receptor polypeptides may also be analogs or naturally-occurring variants of the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16. Such analogs are generated by amino acid substitutions, deletions and/or insertions using methods available in the art. Polypeptides of the invention are preferably the product of expression of an exogenous DNA sequences, i.e., EPH-like receptors are preferably produced by recombinant means. Methods of producing EPH-like receptors comprising culturing host cells which have been transformed or transfected with vectors expressing an EPH-like receptor are also encompassed. EPH-like receptors, particularly fragments, may also be produced by chemical synthesis. The polypeptides so produced may be glycosylated or nonglycosylated depending upon the host cell employed, or may have a methionine residue at the amino terminal end. The polypeptides so produced - 11 - are identified and recovered from cell cultures employing methods which are conventional in the art. EPH-like receptors of the present invention are used for the production of antibodies to the receptors. Antibodies to HEK receptors have been described in Example 4. Antibodies which recognize the polypeptides of the invention may be polyclonal or monoclonal and may be binding fragments or chimeric antibodies. Such antibodies are useful in the detection of EPH-like receptors in diagnostic assays in the purification of receptor, and in the modulation of EPH-like receptor activation. As described in co-pending and co-owned U.S. Serial No. 08/145,616, the only known ligand for an EPH-like receptor is a protein which binds to and induces phosphorylation of the eck receptor. The ECK receptor ligand was previously identified as B61. (Holzman et al. Mol. Cell. Biol. J2, 5830-5838 (1990)). The availability of ECK receptor was important for the identification of a ligand since B61, although known, had not been previously implicated as an ECK receptor ligand. Therefore, EPH-like receptors having ligand binding domains are useful for the identification and purification of ligands. Polypeptides of the present invention may be used to identify and purify ligands for HEK5, HEK7, HEK8 and HEKll receptors. Binding assays for the detection of potential ligands may be carried out in solution or by receptor immobilization on a solid support using methods such as those described in co-pending and co-owned U.S. Serial No. 08/145,616. Such assays may employ an isolated ligand binding domain of a HEK receptor. Alternatively, a HEK ligand binding domain fused to an Ig domain may be used to detect the presence of HEK ligand on cell surfaces. - 12 - Soluble EPH-like receptors may be used to modulate (i.e., increase or decrease) the activation of the cell-associated receptors, typically by competing with the receptor for unbound ligand. Modulation of EPH-like receptor activation may in turn alter the proliferation and/or differentiation of receptor-bearing cells. For example, based upon the observed tissue distribution of the receptors of this invention (see Table 5) , soluble HEK7 receptor is likely to primarily affect proliferation and/or differentiation of brain cells, while soluble HEK5 receptor may affect primarily brain and pancreatic cells, although effects of HEK5 receptor on other tissues may not be excluded. Antibodies to EPH-like receptors are useful reagents for the detection of receptors in different cell types using immunoassays conventional to the art. Antibodies are also useful therapeutic agents for modulating receptor activation. Antibodies may bind to the receptor so as to directly or indirectly block ligand binding and thereby act as an antagonist of receptor activation. Alternatively, antibodies may act as an agonist by binding to receptor so as to faciliate ligand binding and bring about receptor activation at lower ligand concentrations. In addition, antibodies of the present invention may themselves act as a ligands by inducing receptor activation. It is also contemplated that antibodies to EPH-like receptors are useful for selection of cell populations enriched for EPH-like receptor bearing cells. Such populations may be useful in cellular therapy regimens where it is necessary to treat patients which are depleted for certain cell types. The isolated nucleic acids of the present inventions may be used in hybridization assays for the detection and quantitation of DNA and/or RNA coding for HEK5, HEK7, HEK8, HEKll and related receptors. Such assays are important in determining the potential of various cell types to express these receptors and in determining actual expression levels of HEK receptors. In addition, the nucleic acids are useful for detecting abnormalities in HEK receptor genes, such as translocations, rearrangements, duplications, etc. Therapeutic regimens involving EPH-like receptors will typically involve use of the soluble form of the receptor contained in a pharmaceutical composition. Such pharmaecutical compositions may contain pharmaceutically acceptable carrier, diluents, fillers, salts, buffers, stabilizers and/or other materials well known in the art. Further examples of such constituents are described in Remington's Pharmaceutical Sciences 18th ed., A.R. Gennaro, ed. (1990) . Administration of soluble EPH-like receptor compositions may be by a variety of routes depending upon the condition being treated, although typically administration will occur by intravenous or subcutaneous methods. Pharmaceutical compositions containing antibodies to EPH-like receptors will preferably include mouse-human chimeric antibodies or CDR-grafted antibodies in order to minimize the potential for an immune response by the patient to antibodies raised in mice. Other components of anti-EPH antibody compositions will be similar to those described for soluble receptor. The amount of soluble Eph-like receptors or anti-Eph antibody in a pharmaceutical composition will depend upon the nature and severity of the condition being treated. Said amount may be determined for a given patient by one skilled in the art. It is contemplated that the pharmaceutical compositions of the present invention will contain about 0.01 μg to about 100 mg of soluble receptor or anti-Eph antibody per kg body weight. A method for modulating the activation of an EPH-like receptor PTK is also provided by the invention. In practicing this method, a therapeutically effective amount of a soluble EPH-like receptor or an anti-EPH antibody is administered. The term "therapeutically effective amount" is that amount which effects an increase or decrease in the activation of an EPH-like receptor and will range from about 0.01 μg to about 100 mg of soluble receptor or anti-EPH antibody per kg body weight. In general, therapy will be appropriate for a patient having a condition treatable by soluble receptor or anti-EPH antibody and it is contemplated that such a condition will in part be related to the state of proliferation and/or differentiation of receptor-bearing cells. Based upon the tissue distribution of HEK receptors shown in Table 4, treatment with the pharmaceutical compositions of the invention may be particularly indicated for disorders involving brain, heart, muscle, lung, or pancreas. However, some HEK receptors are displayed on a wide variety of tissues, so it is understood that the effects of modulating receptor activation may not be limited to those tissues described herein. The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof. Recombinant DNA methods used in the following examples are generally as described in Sambrook et al. Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press, 2nd ed. (1989) EXAMPLE 1 Cloninσ and Sequencing of HEK Receptor cDNA We have isolated clones for five members of the EPH sub-family of receptor PTKs from a human fetal brain cDNA library. Oligonucleotides were designed based on conserved amino acid sequences within the kinase domain. Primer I was based on the amino acid sequence Trp-Thr-Ala-Pro-Glu-Ala-Ile (SEQ ID NO: 1), which is well-conserved among PTKs of many families. Primer II was based on the sequence Val-Cys-Lys-Val-Ser- Asp-Phe-Gly (SEQ ID NO: 2), which is invariant among EPH sub-family members but, except for the sequence Asp-Phe- Gly, is rarely found in other PTKs. Fully degenerate oligonucleotides corresponding to reverse translations of these protein sequences were synthesized and utilized as primers in a polymerase chain reaction (PCR) with disrupted phage from a human fetal brain cDNA library as the template. The products of this PCR reaction were cloned into the plasmid vector pUC19 and the nucleotide sequence of the inserts was determined. Of the 35 PCR inserts sequenced, 27 were recognizable as portions of PTK genes. Their correspondence to previously published sequences is summarized in Table 1. TABLE 1 Receptor PCR Products Number of Clones Elk VCKVSDFGLSRYLQDDTSDPTYTSSLGGKIPVR TAPEAI (SEQ ID NO: 3) 2 HEK4, HEK7 VCKVSDFGLSRVLEDDPEAAYTT RGGKIPIRWTAPEAI (SEQ ID NO: 4) 5* HEK5 VCKVSDFGLSRFLEDDTSDPTYTSALGGKIPIR TAPEAI (SEQ ID NO: 5) σ I HEK8 VCKVSDFGMSRVLEDDPEAAYTT RGGKIPIRWTAPEAI (SEQ ID NO: 6) HEKll VCKVSDFGLSRVIEDDPEAVYTTT GGKIPVRWTAPEAI (SEQ ID NO: 7) SRC VCKVSDFGLAR LIEDNEYTARQ GAKFPIKWTAPEAI (SEQ ID NO: 8) 6* PDGF-β VCKVSDFGLARDIMRDSNYISK GSTFLPLKWTAPEAI (SEQ ID NO: 9) An asterisk indicates that different nucleic acid sequences encoded the amino acid sequence shown. Six PCR inserts predict amino acid sequences which are identical to a portion of SRC, although they comprise two distinct nucleotide sequences. One insert appears to code for the human platelet derived growth factor (PDGF) -β receptor. The remaining 18 PCR inserts consist of 6 distinct nucleotide sequences, all of which appear to be fragments of EPH sub-family members. One of the sequence predicts an amino acid sequence identical to the corresponding region of rat Elk (Lhotak et al., 1991)) and is likely to represent its human homolog. Two inserts predict amino acid sequences which match the translation of the PCR fragment tyro-4 (Lai and Lemke, 1991) ) but are clearly distinct at the nucleotide level while two others correspond to tyro-1 and tyro-5. The sixth PCR insert has a previously unreported EPH-related sequence. Since five of the clones contained portions of potential EPH sub-family members for which full-length sequences had not been reported, each was radiolabeled and used as a probe to screen a human fetal brain cDNA library. Several clones corresponding to each of the five probes were isolated. For each of the five receptors, the nucleotide sequence of the clone containing the largest portion of the predicted coding region was determined. A single cDNA clone containing the complete coding region was isolated only for HEK4. The portions of HEKS, HEK7, HEK10 and HEKll coding for the amino terminus of these receptors were not found in any of the clones. In order to obtain the complete coding sequence, the Rapid Amplification of cDNA Ends (RACE) technique was employed. In some cases, more than one round of RACE was necessary to obtain the missing portion of the coding region. Using this strategy, complete coding sequences were obtained for all clones except HEK1 which lacked the complete leader sequence. The DNA sequences of HEK5, HEKl , HEK8 and HEKll are shown in Figures 1-4, respectively, and in SEQ ID NO: 10 (HEK5), SEQ ID NO: 12 (HEK7) , SEQ ID NO: 14 (HEK 8) and SEQ ID NO: 16 (HEKll) . The amino acid sequences are shown in SEQ ID NO: 11 (HEK5) , SEQ ID NO: 13 (HEK7) , SEQ ID NO: 15 (HEK8) and SEQ ID NO: 17 (HEK 11) . EXAMPLE 2 Analysis of HEK Receptor Sequences HEK5, HEK7, HEK8 and HEKll represent novel human EPH sub-family members, although homologs for all except HEKll have been isolated from other species. We refer to human EPH receptor sub-family members as HEKs (human EPH-like kinases) following the nomenclature of Wicks et al., 1992) . We have chosen names and numbers for these receptors to correspond with previously discovered members of the family in chicken (Ceks) and in mouse (Mek) (Sajjadi et al. 1991; Sajjadi and Pasquale, 1993; Pasquale, 1991) . Extending the convention of designating the species of origin by the first letter, we refer to the rat homologs of the HEK receptors as Reks (rat EPH-like kinases) . HEK4 is the human homolog of the chicken receptor Cek4 (91% amino acid identity in the catalytic domain) and the mouse receptor Mek4 (96% amino acid identity in the catalytic domain) . The amino acid sequence of HEK5 is very closely related (96% amino acid identity in the catalytic domain) to the chicken receptor Cek5 (Pasquale et al. J. Neuroscience 22., 3956- 3967 (1992); Pasquale, 1991). HEK7 is probably the human homolog of the recently reported Cek7 (Sajjadi and Pasquale, 1993) . HEK8 is likewise very closely related to Sek (Gilardi-Hebenstreit et al., 1992)) and Cekδ (95% amino acid identity in the catalytic domain) (Sajjadi and Pasquale, 1993) ) . The human homologs for Cek6 and Cek9 have yet to be reported, while the human homolog of CeklO has just recently been published. One of our human receptors has no close relatives in other species and apparently represents a novel member of the EPH sub¬ family. We have designated this receptor HEKll, assuming that human homologs for Cek 9 and 10 will be named HEK9 and HEK10, respectively. A summary of known EPH sub-family members is shown in Table 2. TABLE 2 EPH receptor sub-family members Human Non-human homologs EPH None identified ECK None identified None identified* Eek HEK4* Cek4, Mek4 HEK5 Cek5, Nuk, ERK None identified* Cek6, Elk HEK7 Cek7, Ehkl HEK8 Cek8, Sek None identified* Cek9 HEK2 CeklO HEKll None identified None identified Ehk2 -- • published by Wicks et.al., 1992 as HEK #Using the present nomenclature, the predicted human homolog of Eek is designated HEK3. For Cek6, the predicted human homolog is designated HEK6; For Cek9, the predicted human homolog is designated HEK9. The predicted amino acid sequences of the four novel receptor clones and the previously known EPH sub-family members ECK (SEQ ID NO: 18), EPH (SEQ ID NO: 19), HEK2 (SEQ ID NO: 20) and HEK4 (SEQ ID NO: 21) were aligned as shown in Fig. 5. The four clones are closely related to each other and to the known EPH sub-family members. The extracellular domain sequences of all four novel receptors contain the Ig-loop, fibronectin-type III repeats, and cysteine-rich region characteristic of EPH sub-family members. The positions of the 20 cysteine residues are conserved among all sub-family members. Also completely conserved is the portion of the catalytic domain used as the basis for the EPH sub- family specific primer (Val-Cys-Lys-Val-Ser-Asp-Phe-Gly, SEQ ID NO: 2, amino acids 757-764 in Fig. 5) . Table 3 summarizes the percentage of sequence identity between pairs of human EPH sub-family members. The lower portion of the table shows percent amino acid identity in the catalytic domain while the upper half shows percent amino acid identity in the extracellular region. The amino acid sequences of the EPH-like receptors are extremely well-conserved (60-89% amino acid identity) in the catalytic region but not as highly conserved in the extracellular region (38-65% amino acid identity) , as would be expected for members of the same receptor sub¬ family. TABLE 3 Eph family amino acid sequence comparison extracellular domains EPH ECK HEK4 HEK5 HEK7 HEK8 HEK2 HEKll EPH * 47 42 38 40 43 40 42 ECK 62 * 47 41 45 46 41 46 HEK4 62 76 * 53 65 61 51 59 HEK5 60 74 81 * 52 53 63 51 HEK7 61 76 89 83 * 62 48 61 HEK8 62 76 86 85 88 * 52 57 HEK2 61 74 81 89 82 83 * 48 HEKll 60 74 83 83 85 85 80 * Catalytic domains Numbers shown are precent identity Pairwise comparisons of amino acid sequences can be used to construct phylogenetic trees depicting the evolutionary relatedness of a family of molecules. Figure 6 is such a tree, which summarizes the relationships among the EPH sub-family members. Only one family member is shown from each group of cross- species homologs and the human representative was used whenever possible (refer to Table 2 for a summary of cross-species homologs) . The branch lengths represent the degree of divergence between members. It has been shown previously that the EPH sub-family lies on a branch evolutionarily closer to the cytoplasmic PTKs than to other receptor PTKs (Lindberg and Hunter, 1993) . Interestingly, the further one moves up the tree, the more closely related the receptors become and expression becomes more localized to the brain. EXAMPLE 3 Construction and Expression of HEK Receptor Extracellular Domains Soluble extracellular forms of HEK receptor proteins were constructed by deletion of DNA sequences encoding transmembrane and cytoplasmic domains of the receptors and introduction of a translation stop codon at the 3' end of the extracellular domain. A construct of the HEK5 extracellular domain had a stop codon introduced after lysine at position 524 as shown in Figure 1; the HEK7 extracellular domain was constructed with a stop codon after glutamine at position 547 as shown in Figure 2; the HEK 8 extracellular domain was constructed with a stop codon after threonine at position 547 as shown in Figure 3. HEK extracellular domain was amplified from a human fetal brain cDNA library by PCR using primers 5' and 3' to the extracellular domain coding region. For HEK5, the primers 5' CTGCTCGCCGCCGTGGAAGAAACG (SEQ ID NO: 22) and; 5 1 GCGTCTAGATTATCACTTCTCCTGGATGCTTGTCTGGTA (SEQ ID NO: 23) were used to amplify the extracellular domain and to provide a restriction site for cloning into plasmid pDSRα. In addition, the following primers were used to provide a translational start site, the elk receptor signal peptide for expression; and a restriction site for cloning into pDSRα: 5' GCGGTCGACGCCGCCGCCATGGCCCTGGATTGCCTGCTGCTGTTCCTCCTG (SEQ ID NO: 24) and; 5 • CGTTTCTTCCACGGCGGCGAGCAGAGATGCCAGGAGGAACAGCAGCAGGCA ATC (SEQ ID NO: 25) The resulting construct resulted in fusion of DNA encoding the elk signal sequence Met-Ala-Leu-Asp- Cys-Leu-Leu-Leu-Phe-Leu-Leu-Ala-Ser (SEQ ID NO: 26) to the first codon of the HEK5 receptor. The resulting HEK5 extracellular domain was cloned into pDSRα after digestion with Sail and Xbal and transfected into CHO cells for expression. HEK8 extracellular domain was amplified from a human fetal brain cDNA library by PCR using primers 5' and 3' to the extracellular domain coding region. For HEK8, the primers 5' GAATTCGTCGACCCGGCGAACCATGGCTGGGAT and 5' GAATTCTCTAGATTATCATGTGGAGTTAGCCCCATCTC were used to amplify the extracellular domain and to provide restriction sites for cloning into plasmid pDSRα. The resulting HEK8 extracellular domain was cloned into pDSRα after digestion with Sail and Xbal and transferred CHO cells for expression. HEK7 extracellular domain was amplified from a human fetal brain cDNA library by PCR using primers 5' and 3' to the extracellular domain coding region. For HEK7, the primers 5'TTCGCCCTATTTTCGTGTCTCTTCGGGATTTGCGACGCTCTCCGGACCCTCCTG GCCAGC and 5' GAATTCTCTAGATTATCACTGGCTTTGATCGCTGGAT were used to amplify the extracellular domain. In addition, the following primers were used to provide a translational start site, the HEK8 receptor signal peptide sequence, and restriction site for cloning into plasmid pDSRα. 5' GAATTCGTCGACCCGGCGAACCATGGCTGGGATTTTCTATTTCGCCCTATTTTCGT GTCT 5 1 GAATTCTCTAGATTATCACTGGCTTTGATCGCTGGAT The resulting construct resulted in fusion of DNA incoding HEK8 signal sequence Met-Ala-Gly-Ile-Phe- Tyr-Phe-Ala-Leu-Phe-Ser-Cys-Leu-Phe-Gly-Ile-Cys-Asp to the first codon of the HEK7 receptor. The resulting HEK7 extracellular domain was cloned into pDSRα after digestion with Sail and Xbal and transfected into CHO cells for expression. EXAMPLE 4 Antibodies to HEK Receptors Antibodies to HEK receptor proteins were generated which recognize the extracellular domain by using bacterial fusion proteins as the antigen. Antibodies were also generated which recognize the cytoplasmic domain by using synthetic peptides as the antigen. The methodology employed has been previously described (Harlow and Lane, In Antibodies: A Laboratory Manual. 1988) . For the extracellular domain antibodies, cDNAs were inserted into the pATH vector (see Table 4 for the regions of each receptor encoded by this construct) . These constructs were expressed in bacteria and the resultant TrpE-fusion proteins were purified by SDS-polyacrylamide gel electrophoresis. For the cytoplasmic domain anti-peptide antibodies, peptides were synthesized (see Table 4 for the sequences) and covalently coupled to keyhole limpet hemocyanin . The fusion proteins and coupled peptides were used as antigens in rabbits and antisera were generated and characterized as described (Harlow and Lane, 1988) . Anti-peptide antibodies were affinity purified by using a SulfoLink kit (Pierce, Rockford IL) . TABLE 4 HEK Receptor Antigens Amino Acids in Receptor Peptide Sequences Fusion Protein HEK4 CLETQSKNGPVPV 22-159 HEK5 CRAQMNQIQSVEV 31-168 HEK7 CMKVQLVNGMVPL 335-545 HEK8 CMRTQMQQMHGRMVPV 27-188 HEKll CQMLHLHGTGIQV 187-503 EXAMPLE 5 HEK/TrkB Chimeric Receptors 1. Generation of pSJAl encoding rat trkB cytoplasmic domain. All of the chimeric receptors are composed of the extracellular domain and the transmembrane region of one of the HEK receptors and the intracellular portion of rat trkB. To simplify each individual construction, an intermediate or parental plasmid, called RtrkB/Aflll (or pSJAl) , was generated. First, without altering the coded peptide sequence, an Aflll site (CTTAAG) was introduced into position 2021 (cytosine at position 2021 (C2021) to guanine at position 2026 (G2026, CTCAAG) of the rat trkB cDNA (Middlemas, et al., Mol. Cell. Biol. 11. 143-153 (1991)) by PCR aided mutagenesis. Briefly, PCR primers were synthesized based on the rat trkB cDNA sequence. Primer I encompassed C2003 to G2034 of the cDNA. This primer contained two mutations, a cytosine to thymine(T) substitution at position 2023 (C2023T) and an insertion of an adenine (A) in between T2013 and G2014. These mutations created the Aflll site at position C2021 and an additional Xhol site flanking the Aflll site. Primer II was in the reverse direction encompassing T2141 to A2165 of the cDNA which bore an Apal site. The PCR fragment produced with these primers and the rat trkB cDNA template was digested with Xhol and Apal enzymes and sub cloned into the Xhol and Apal sites of an expression vector, pcDNA3 (InVitroGen) , to generate pSJAl-b. Following, pSJAl-b was linearized with Apal and ligated with a Banll digested rat trkB cDNA fragment (G2151 to G4697) to reconstitute a larger fragment (C2021 to G4697) including the coding sequence of the whole intracellular domain of the rat trkB protein (L442 to G790) and 1571 residues (A3131 to G4697) of the 1627 nucleotide 3'-end non-coding region of the cDNA. 2. Generation of HEK8/rat trkB (pSJA5) chimera. HEK8/rat trkB chimera was generated with a similar strategy as mentioned above. A Sall/Bsal cDNA fragment was first isolated from plasmid TK10/FL13. This fragment included the nucleotide sequence from the beginning to T1689 of the HEK8 cDNA (Figure 3) . Then, a pair of oligonucleotides was synthesized based on the HEK8 cDNA sequence. The sequence of the first oligonucleotide was the same as G1690 to C1740 of the Hek8 cDNA, with an additional C residue added to its 3'- end. The second oligonucleotide was in the reverse orientation of the HEK8 cDNA. It contained C1694 to C1740 of the HEK8 cDNA sequence and an additional five residue motif, TTAAG, at its 5'-end. These two oligonucleotides were kinased and annealed with equal molar ratio, to create a double strand DNA fragment with the sequence of G1690 to C1740 of the HEK8 cDNA and with the Bsal and the Aflll cohesive ends at its 5* and 3' ends, respectively. This fragment was ligated together with the Sall/Bsal cDNA fragment into Xhol/Aflll linearized pSJAl to generate the HEK8/RtrkB (pSJA5) chimerical construct. 3. Generation of HEKll/rat trkB (pSJA6) chimera. To generate the HEKll/rat trkB chimera, a Sall/AccI fragment covering the sequence of nucleotide Cl to T1674 of the HEKll cDNA (Figure 4) was first isolated from plasmid TK19T3. Then, a pair of oligonucleotides was synthesized based on the HEKll cDNA sequence. The first oligonucleotide had the same sequence as from nucleotide A1666 to T1691 of the HEKll cDNA, which contained the AccI site. The second oligonucleotide was in the reverse orientation of the HEKll cDNA. It encompassed G1895 to T1919 of the HEKll cDNA sequence. An additional ten residue motif, CCCGCTTAAG, was added to the 5'-end of this oligonucleotide to introduce an Aflll site, which would be used to link the external domain and the transmembrane region of the HEKll receptor to the intracellular domain of the rat trkB cDNA cloned in pSJAl in the same reading frame. PCR was performed with these oligonucleotides as primers and the HEKll cDNA as template. The PCR fragment was digested with AccI and Aflll enzymes and ligated with the Sall/AccI cDNA fragment and the Xhol/Aflll linearized pSJAl to generate the HEKll/rat trkB (pSJA6) chimerical construct. EXAMPLE 6 Tissue Distribution of HEK Receptors The distribution of RNA expression for HEK4, HEK5, HEK7, HEK8 and HEKll receptors in human and rat tissues was examined by Northern blot hybridization. Rat total RNA was prepared from tissues using the method of Chomczynski and Sacchi (Anal. Biochem 162 f 156-159 (1987)). The RNA was separated by formaldehyde- agarose electrophoresis and transferred to Hybond-N membranes (Amersham, Arlington Heights, IL) using 2OX SSC (Maniatis et al. 1982) . The membrane was dried at 80°C in vacuo for 30 minutes, then crosslinked for 3 minutes on a UV transilluminator (Fotodyne, New Berlin, WI) . The membrane was prehybridized for 2 hours at 42°C in 50% formamide, 5X SSPE, 5X Denhardt's, 0.2% SDS, and 100 μg/ml denatured herring sperm DNA (Maniatis et al. 1982) . Northern blots of human tissue were purchased from Clontech (Palo Alto, CA) . Probes were prepared by labeling the fragment of cDNA which encoded the extracellular domain of the receptor with 3 2 P-dCTP using a hexanucleotide random priming kit (Boehringer Mannheim, Indianapolis, IN) to a specific activity of at least 1x109 cpm/ug. The probe was hybridized to the membrane at a concentration of 1-5 ng/ml at 42°C for 24 to 36 hours in a buffer similar to the prehybridization •buffer except that IX Denhardt's was used. After hybridization, the membranes were washed 2 times for 5 minutes each in 2X SSC, 0.1% SDS at room temperature followed by two 15 minute washes in 0.5X SSC, 0.1% SDS at 55°C. Blots were exposed for 1-2 weeks using Kodak XAR film (Kodak, Rochester, NY) with a Dupont Lightning Plus intensifying screen. The results are shown in Figures 7-11. Homologs for HEK4 have been previously identified from mouse, chicken, and rat. In the adult mouse, expression is detected primarily in the brain and testis (Sajjadi et al. 1991) . A slightly different pattern was found in adult chicken tissues, with the main sources of expression being the brain, liver, and kidney. Lower levels of expression were detectable in the lung and heart (Marcelle & Eichmann, Oncogene 7. . 2479-2487 (1992) ) . A fragment of the Rek4 gene (tyro-4) has been isolated and used to look at tissue expression in the adult rat (Sajjadi et al. 1991) . The brain was the only tissue that expressed Rek4 mRNA. However, RNA from lung or testis were not examined. Previous studies on HEK4 only looked at the expression of the mRNA in cell lines, where it was found in one pre-B cell line and two T-cell lines (Wicks et al. 1992) . The significance of this with regard to in vivo expression remains to be determined. In this study we have looked at the HEK4 expression in human tissues, and also the expression of Rek4 in rat tissues. The HEK4 mRNA corresponds to a single transcript with a size of about 7 kb (Fig 7A) . HEK4 mRNA was most abundantly expressed in placenta, with lower levels present in heart, brain, lung, and liver. On prolonged exposures, trace amounts of mRNA were detectable in kidney and pancreas. Expression in the rat was more similar to that detected in the mouse and chicken. Rek4 was expressed at the lowest levels of any of the family members characterized herein. A transcript of about 7 kb was detectable in rat lung, with a lower amount detectable in brain (Fig. 7B) . Also, a 4 kb transcript was expressed in rat testis. Because the transcripts were barely detectable using total RNA, some of the other rat tissues may contain amounts of Rek4 below the level of detection. The expression of HEK5 in adult tissues has been previously studied in chicken and rat. Studies in the chicken have identified the Cek5 protein in the brain and liver, with a smaller protein detected in the intestine. In the rat, the tyro-5 fragment detected mRNA expression only in the adult brain, though intestine was not examined (Lai and Lemke, 1991) . Our results show that HEK5 mRNA was expressed at much higher levels than HEK4 and was found as transcripts of several sizes. The most abundant mRNAs were of approximately 4.0 and 4.4 kb, with lesser amounts of higher molecular weight transcripts of 9.5 kb and longer (Fig. 8A) . The HEK5 mRNA was most abundantly expressed in placenta, but was also highly expressed in brain, pancreas, kidney, muscle, and lung. Longer exposures of the blots revealed the presence of transcripts in heart and liver as well. The rat homolog of HEK5 (Rek5) showed a somewhat similar pattern of expression. Rek5 was most abundant in intestine, followed by brain, kidney, lung, thymus, stomach, and ovary (Fig. 8B) . Expression was not detectable in testis, muscle, heart, or liver. During our analysis of this family, we concluded that the rat Erk fragment (Chan & Watt, 1991) likely encodes a portion of the Rek5 receptor. Erk expression was examined in several rat tissues and found only in the lung. The reason for the discrepancy between that report and what we and others (Lai & Lemke, 1991) have found is unclear. Homologs for HEK8 have been identified from chicken, mouse, and rat. In the adult chicken, a single Cek8 transcript was found to be expressed at high levels in the brain, with expression also detected in the kidney, lung, muscle, and thymus. The expression of the mouse homolog of HEK8, Sek, has been detected as a single transcript with abundant expression in the adult brain and lower expression in the heart, lung and kidney. A fragment of Rek8 (tyro-1) was used to look at expression in rat tissues, with expression found only in the brain (Lai & Lemke, 1991) . We found that HEK8 mRNA was expressed at levels comparable to that of HEK5. Multiple transcripts were also observed, the most abundant at 7 kb and 5 kb. The highest level of mRNA expression was seen in the brain, although substantial levels were detected in other tissues including heart, lung, muscle, kidney, placenta, and pancreas. Expression in liver was much lower than in the other tissues. The only difference in expression patterns between human and mouse was expression in human muscle, also seen for Cek8 in chicken. Among the rat tissues, Rek8 was most highly expressed in the brain, followed by the lung, heart, and testis (Fig. 10B) . In contrast to HEK8, expression of Rek8 appeared to be lower in muscle and kidney, two tissues where HEK8 was readily detectable. In addition, Rek8 was not expressed as a 5.0 kb transcript, as it was not visible even on prolonged exposures. During the analysis of this family, we deduced that HEK7 is the human homolog of Cek7. The only expression seen in adult chicken was an 8.5 kb transcript found in the brain (Sajjadi & Pasquale, 1993) . Of the five EPH sub-family members described here, HEK1 was the most restricted in its expression pattern. Analysis of human mRNA revealed significant expression only in the brain, with a much lower level detectable in the placenta (Fig. 9A) . Prolonged exposures did not reveal expression in any other tissue examined. Two prominent transcripts were found in brain, the most highly expressed with a size of 6 kb and the other with a length of 9 kb. In the placenta, however, only the 9 kb transcript was detected. Rek7 mRNA was expressed in a pattern similar to HEK7. The highest level of expression was found in brain, with a much lower level in ovary (Fig. 9B) . The transcripts were of similar size as for HEK7, with the 6 kb transcript detected only in brain. HEKll was expressed as several transcripts, with major mRNAs of length 7.5, 6.0 and 3.0 kb and minor transcripts of 4.4 and 2.4 kb (Fig. 11A) . All five mRNAs were expressed at the highest levels in brain, followed by heart. Placenta, lung and kidney had significant amounts of four of the five transcripts, with lower expression seen in muscle. Pancreas had barely detectable amounts of HEKll mRNA, while liver had no detectable HEKll transcript. Rekll had a similar pattern of expression, with four transcripts (10, 7.5, 3.5 and 3.0 kb) detected in brain (Fig. 11B) . The relative level of mRNA expression for each of the five receptors in all tissues studied is summarized in Table 5. TABLE 5 Tissue Distribution of HEK Receptors Human HEK4 HEK5 HEK7 HEK8 HEKll Brain ++ ++ ++ +++ ++ Heart + + bd ++ + Kidney + + bd + + Liver + + bd + bd Lung + + bd ++ + Muscle + + bd ++ + Pancreas + ++ bd + bd Placenta +++ +++ bd ++ + Rat HEK4 HEK5 HEK7 HEK8 HEKll Brain + ++ +++ +++ ++ Heart bd bd bd + bd Intestine bd +++ bd bd bd Kidney bd ++ bd bd bd Liver bd bd bd bd bd Lung + + bd ++ bd Muscle bd bd bd bd bd Ovary bd + + bd bd Stomach bd + bd bd bd Testis + bd bd + bd Thymus bd + bd bd bd bd= below detection The transcripts for HEKs 4,5,8, and 11 were rather widely distributed in human tissue while HEK7 was specific for brain. Expression patterns between rat and human tissue were roughly comparable given that the rat blots were less sensitive due to the use of total RNA rather than polyA + . As was found for the Cek mRNAs by Sajjadi and Pasquale (Sajjadi & Pasquale, 1993), often there were several different size transcripts detected for a single receptor. The size distribution of the transcripts appears to be both tissue and species specific. Previous work has shown that the smaller transcript of Mek4 encodes a potentially secreted receptor (Sajjadi et al. 1991) . The following sections describe Materials and Methods used to carry out experiments described in Example 1. Isolation, cloninσ and sequencing of HEK receptor cDNAs Fragments containing a portion of the catalytic domain of EPH sub-family receptors were generated using a polymerase chain reaction (PCR) with disrupted phage from a human fetal brain cDNA library as a template. A lOμl aliquot of the cDNA library (Stratagene, La Jolla, CA) was treated at 70°C for 5 minutes to disrupt the phage particles, then cooled on wet ice. The disrupted phage were added to lOμl of 10X Tag polymerase buffer, 8ul of 2mM each dNTP, 100 picomoles of each primer, and 1.5 μl of Tag polymerase (Promega, Madison, WI) in a total volume of lOOμl. The reaction was run for 35 cycles, each consisting of 1 minute at 96°C, 1 minute at 50°C, and 2 minutes at 72°C. A 5 minute, 72°C incubation was added at the end to ensure complete extension. The primers used were degenerate mixtures of oligonucleotides based on amino acid sequences which are highly conserved among EPH sub-family members. 5'AGGGAATTCCAYCGNGAYYTNGCNGC (SEQ ID NO: 27); 5'AGGGGATCCRWARSWCCANACRTC (SEQ ID NO: 28) . The products of the PCR reaction were digested with EcoRI and BamHI and cloned into M13mpl9 (Messing, Methods Enzymol. (1983)) for sequence analysis. The five clones which were identified as fragments of EPH receptor sub-family members were labeled with ^P-dCTP by random priming and each was used to screen Genescreen nitrocellulose filters (NEN, Boston, MA) containing plaques from the human fetal brain cDNA library. Phage stocks prepared from positively screening plaques were plated and rescreened with the same probe in order to obtain single clones. cDNA inserts were transferred into pBluescript using the in vivo excision protocol supplied with the cDNA library (Stratagene, La Jolla, CA) . Nucleotide sequences were determined using Taq DyeDeoxy Terminator Cycle Sequencing kits and an Applied Biosystems 373A automated DNA sequencer (Applied Biosystems, Foster City, CA) . 5' Race The 5' ends of the cDNAs were isolated using a 5' RACE kit (GIBCO/BRL, Gaithersburg, MD) following the manufacturer's instructions. Excess primers were removed after first strand cDNA synthesis using ultrafree-MC cellulose filters (30,000 molecular weight cutoff, Millipore, Bedford, MA) . Amplified PCR products were digested with the appropriate restriction enzymes, separated by agarose gel electrophoresis, and purified using a Geneclean kit (BiolOl, La Jolla, CA) . The purified PCR product was ligated into the plasmid vector pUC19 (Yanisch-Perron et al. Gene 2A, 103-119 (1985)) - 36 - which had been digested with appropriate restriction enzymes and the ligation mixture was introduced into host bacteria by electroporation. Plasmid DNA was prepared from the resulting colonies. Those clones with the largest inserts were selected for DNA sequencing. While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Amgen Inc. (ii) TITLE OF INVENTION: EPH-Like Receptor Protein Tyrosine Kinases (iii) NUMBER OF SEQUENCES: 28 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Amgen Patent Operations/RBW (B) STREET: 1840 Dehavilland Drive (C) CITY: Thousand Oaks (D) STATE: California (E) COUNTRY: USA (F) ZIP: 91320 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Winter, Robert B. (C) REFERENCE/DOCKET NUMBER: A-287 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l Trp Thr Ala Pro Glu Ala lie 1 5 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Val Cys Lys Val Ser Asp Phe Gly 1 5 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Tyr Leu Gin Asp Asp 1 5 10 15 Thr Ser Asp Pro Thr Tyr Thr Ser Ser Leu Gly Gly Lys lie Pro Val 20 25 30 Arg Trp Thr Ala Pro Glu Ala lie 35 40 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Val Leu Glu Asp Asp 1 5 10 15 Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly Lys lie Pro lie Arg Trp 20 25 30 Thr Ala Pro Glu Ala lie 35 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Phe Leu Glu Asp Asp 1 5 10 15 Thr Ser Asp Pro Thr Tyr Thr Ser Ala Leu Gly Gly Lys lie Pro He 20 25 30 Arg Trp Thr Ala Pro Glu Ala He 35 40 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Val Cys Lys Val Ser Asp Phe Gly Met Ser Arg Val Leu Glu Asp Asp 1 5 10 15 Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly Lys He Pro He Arg Trp 20 25 30 Thr Ala Pro Glu Ala He 35 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7 : Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Val He Glu Asp Asp 1 5 10 15 Pro Glu Ala Val Tyr Thr Thr Thr Gly Gly Lys He Pro Val Arg Trp 20 25 30 Thr Ala Pro Glu Ala He 35 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Val Cys Lys Val Ser Asp Phe Gly Leu Ala Arg Leu He Glu Asp Asn 1 5 10 15 Glu Tyr Thr Ala Arg Gin Gly Ala Lys Phe Pro He Lys Trp Thr Ala 20 25 30 Pro Glu Ala He 35 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Val Cys Lys Val Ser Asp Phe Gly Leu Ala Arg Asp He Met Arg Asp 1 5 10 15 Ser Asn Tyr He Ser Lys Gly Ser Thr Phe Leu Pro Leu Lys Trp Thr 20 25 30 Ala Pro Glu Ala He 35 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2962 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2913 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CTG CTC GCC GCC GTG GAA GAA ACG CTA ATG GAC TCC ACT ACA GCG ACT 48 Leu Leu Ala Ala Val Glu Glu Thr Leu Met Asp Ser Thr Thr Ala Thr 1 5 10 15 GCT GAG CTG GGC TGG ATG GTG CAT CCT CCA TCA GGG TGG GAA GAG GTG 96 Ala Glu Leu Gly Trp Met Val His Pro Pro Ser Gly Trp Glu Glu Val 20 25 30 AGT GGC T C GAT GAG AAC ATG AAC ACG ATC CGC ACG TAC CAG GTG TGC 144 Ser Gly Tyr Asp Glu Asn Met Asn Thr He Arg Thr Tyr Gin Val Cys 35 40 45 AAC GTG TTT GAG TCA AGC CAG AAC AAC TGG CTA CGG ACC AAG TTT ATC 192 Asn Val Phe Glu Ser Ser Gin Asn Asn Trp Leu Arg Thr Lys Phe He 50 55 60 CGG CGC CGT GGG GCC CAC CGC ATC CAC GTG GAG ATG AAG TTT TCG GTG 240 Arg Arg Arg Gly Ala His Arg He His Val Glu Met Lys Phe Ser Val 65 70 75 80 CGT GAC TGC AGC AGC ATC CCC AGC GTG CCT GGC TCC TGC AAG GAG ACC 288 Arg Asp Cys Ser Ser He Pro Ser Val Pro Gly Ser Cys Lys Glu Thr 85 90 95 TTC AAC CTC TAT TAC TAT GAG GCT GAC TTT GAC TCG GCC ACC AAG ACC 336 Phe Asn Leu Tyr Tyr Tyr Glu Ala Asp Phe Asp Ser Ala Thr Lys Thr 100 105 110 TTC CCC AAC TGG ATG GAG AAT CCA TGG GTG AAG GTG GAT ACC ATT GCA 384 Phe Pro Asn Trp Met Glu Asn Pro Trp Val Lys Val Asp Thr He Ala 115 120 125 GCC GAC GAG AGC TTC TCC CAG GTG GAC CTG GGT GGC CGC GTC ATG AAA 432 Ala Asp Glu Ser Phe Ser Gin Val Asp Leu Gly Gly Arg Val Met Lys 130 135 140 ATC AAC ACC GAG GTG CGG AGC TTC GGA CCT GTG TCC CGC AGC GGC TTC 480 He Asn Thr Glu Val Arg Ser Phe Gly Pro Val Ser Arg Ser Gly Phe 145 150 155 160 TAC CTG GCC TTC CAG GAC TAT GGC GGC TGC ATG TCC CTC ATC GCC GTG 528 Tyr Leu Ala Phe Gin Asp Tyr Gly Gly Cys Met Ser Leu He Ala Val 165 170 175 CGT GTC TTC TAC CGC AAG TGC CCC CGC ATC ATC CAG AAT GGC GCC ATC 576 Arg Val Phe Tyr Arg Lys Cys Pro Arg He He Gin Asn Gly Ala He 180 185 190 TTC CAG GAA ACC CTG TCG GGG GCT GAG AGC ACA TCG CTG GTG GCT GCC 624 Phe Gin Glu Thr Leu Ser Gly Ala Glu Ser Thr Ser Leu Val Ala Ala 195 200 205 CGG GGC AGC TGC ATC GCC AAT GCG GAA GAG GTG GAT GTA CCC ATC AAG 672 Arg Gly Ser Cys He Ala Asn Ala Glu Glu Val Asp Val Pro He Lys 210 215 220 CTC TAC TGT AAC GGG GAC GGC GAG TGG CTG GTG CCC ATC GGG CGC TGC 720 Leu Tyr Cys Asn Gly Asp Gly Glu Trp Leu Val Pro He Gly Arg Cys 225 230 235 240 ATG TGC AAA GCA GGC TTC GAG GCC GTT GAG AAT GGC ACC GTC TGC CGA 768 Met Cys Lys Ala Gly Phe Glu Ala Val Glu Asn Gly Thr Val Cys Arg 245 250 255 GGT TGT CCA TCT GGG ACT TTC AAG GCC AAC CAA GGG GAT GAG GCC TGT 816 Gly Cys Pro Ser Gly Thr Phe Lys Ala Asn Gin Gly Asp Glu Ala Cys 260 265 270 ACC CAC TGT CCC ATC AAC AGC CGG ACC ACT TCT GAA GGG GCC ACC AAC 864 Thr His Cys Pro He Asn Ser Arg Thr Thr Ser Glu Gly Ala Thr Asn 275 280 285 TGT GTC TGC CGC AAT GGC TAC TAC AGA GCA GAC CTG GAC CCC CTG GAC 912 Cys Val Cys Arg Asn Gly Tyr Tyr Arg Ala Asp Leu Asp Pro Leu Asp 290 295 300 ATG CCC TGC ACA ACC ATC CCC TCC GCG CCC CAG GCT GTG ATT TCC AGT 960 Met Pro Cys Thr Thr He Pro Ser Ala Pro Gin Ala Val He Ser Ser 305 310 315 320 GTC AAT GAG ACC TCC CTC ATG CTG GAG TGG ACC CCT CCC CGC GAC TCC 1008 Val Asn Glu Thr Ser Leu Met Leu Glu Trp Thr Pro Pro Arg Asp Ser 325 330 335 GGA GGC CGA GAG GAC CTC GTC TAC AAC ATC ATC TGC AAG AGC TGT GGC 1056 Gly Gly Arg Glu Asp Leu Val Tyr Asn He He Cys Lys Ser Cys Gly 340 345 350 TCG GGC CGG GGT GCC TGC ACC CGC TGC GGG GAC AAT GTA CAG TAC GCA 1104 Ser Gly Arg Gly Ala Cys Thr Arg Cys Gly Asp Asn Val Gin Tyr Ala 355 360 365 CCA CGC CAG CTA GGC CTG ACC GAG CCA CGC ATT TAC ATC AGT GAC CTG 1152 Pro Arg Gin Leu Gly Leu Thr Glu Pro Arg He Tyr He Ser Asp Leu 370 375 380 CTG GCC CAC ACC CAG TAC ACC TTC GAG ATC CAG GCT GTG AAC GGC GTT 1200 Leu Ala His Thr Gin Tyr Thr Phe Glu He Gin Ala Val Asn Gly Val 385 390 395 400 ACT GAC CAG AGC CCC TTC TCG CCT CAG TTC GCC TCT GTG AAC ATC ACC 1248 Thr Asp Gin Ser Pro Phe Ser Pro Gin Phe Ala Ser Val Asn He Thr 405 410 415 ACC AAC CAG GCA GCT CCA TCG GCA GTG TCC ATC ATG CAT CAG GTG AGC 1296 Thr Asn Gin Ala Ala Pro Ser Ala Val Ser He Met His Gin Val Ser 420 425 430 CGC ACC GTG GAC AGC ATT ACC CTG TCG TGG TCC CAG CCG GAC CAG CCC 1344 Arg Thr Val Asp Ser He Thr Leu Ser Trp Ser Gin Pro Asp Gin Pro 435 440 445 AAT GGC GTG ATC CTG GAC TAT GAG CTG CAG TAC TAT GAG AAG GAG CTC 1392 Asn Gly Val He Leu Asp Tyr Glu Leu Gin Tyr Tyr Glu Lys Glu Leu 450 455 460 AGT GAG TAC AAC GCC ACA GCC ATA AAA AGC CCC ACC AAC ACG GTC ACG 1440 Ser Glu Tyr Asn Ala Thr Ala He Lys Ser Pro Thr Asn Thr Val Thr 465 470 475 480 GGC CTC AAA GCC GGC GCC ATC TAT GTC TTC CAG GTG CGG GCA CGC ACT 1488 Gly Leu Lys Ala Gly Ala He Tyr Val Phe Gin Val Arg Ala Arg Thr 485 490 495 GTG GCA GGC TAC GGG CGC TAC AGC GGC AAG ATG TAC TTC CAG ACC ATG 1536 Val Ala Gly Tyr Gly Arg Tyr Ser Gly Lys Met Tyr Phe Gin Thr Met 500 505 510 ACA GAA GCC GAG TAC CAG ACA AGC ATC CAG GAG AAG TTG CCA CTC ATC 1584 Thr Glu Ala Glu Tyr Gin Thr Ser He Gin Glu Lys Leu Pro Leu He 515 520 525 ATC GGC TCC TCG GCC GCT GGC CTG GTC TTC CTC ATT GCT GTG GTT GTC 1632 He Gly Ser Ser Ala Ala Gly Leu Val Phe Leu He Ala Val Val Val 530 535 540 ATC GCC ATC GTG TGT AAC AGA CGG GGG TTT GAG CGT GCT GAC TCG GAG 1680 He Ala He Val Cys Asn Arg Arg Gly Phe Glu Arg Ala Asp Ser Glu 545 550 555 560 TAC ACG GAC AAG CTG CAA CAC TAC ACC AGT GGC CAC ATA ACC CCA GGC 1728 Tyr Thr Asp Lys Leu Gin His Tyr Thr Ser Gly His He Thr Pro Gly 565 570 575 ATG AAG ATC TAC ATC GAT CCT TTC ACC TAC GAG GAC CCC AAC GAG GCA 1776 Met Lys He Tyr He Asp Pro Phe Thr Tyr Glu Asp Pro Asn Glu Ala 580 585 590 GTG CGG GAG TTT GCC AAG GAA ATT GAC ATC TCC TGT GTC AAA ATT GAG 1824 Val Arg Glu Phe Ala Lys Glu He Asp He Ser Cys Val Lys He Glu 595 600 605 CAG GTG ATC GGA GCA GGG GAG TTT GGC GAG GTC TGC AGT GGC CAC CTG 1872 Gin Val He Gly Ala Gly Glu Phe Gly Glu Val Cys Ser Gly His Leu 610 615 620 AAG CTG CCA GGC AAG AGA GAG ATC TTT GTG GCC ATC AAG ACG CTC AAG 1920 Lys Leu Pro Gly Lys Arg Glu He Phe Val Ala He Lys Thr Leu Lys 625 630 635 640 TCG GGC TAC ACG GAG AAG CAG CGC CGG GAC TTC CTG AGC GAA GCC TCC 1968 Ser Gly Tyr Thr Glu Lys Gin Arg Arg Asp Phe Leu Ser Glu Ala Ser 645 650 655 ATC ATG GGC CAG TTC GAC CAT CCC AAC GTC ATC CAC CTG GAG GGT GTC 2016 He Met Gly Gin Phe Asp His Pro Asn Val He His Leu Glu Gly Val 660 665 670 GTG ACC AAG AGC ACA CCT GTG ATG ATC ATC ACC GAG TTC ATG GAG AAT 2064 Val Thr Lys Ser Thr Pro Val Met He He Thr Glu Phe Met Glu Asn 675 680 685 GGC TCC CTG GAC TCC TTT CTC CGG CAA AAC GAT GGG CAG TTC ACA GTC 2112 Gly Ser Leu Asp Ser Phe Leu Arg Gin Asn Asp Gly Gin Phe Thr Val 690 695 700 ATC CAG CTG GTG GGC ATG CTT CGG GGC ATC GCA GCT GGC ATG AAG TAC 2160 He Gin Leu Val Gly Met Leu Arg Gly He Ala Ala Gly Met Lys Tyr 705 710 715 720 CTG GCA GAC ATG AAC TAT GTT CAC CGT GAC CTG GCT GCC CGC AAC ATC 2208 Leu Ala Asp Met Asn Tyr Val His Arg Asp Leu Ala Ala Arg Asn He 725 730 735 CTC GTC AAC AGC AAC CTG GTC TGC AAG GTG TCG GAC TTT GGG CTC TCA 2256 Leu Val Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser 740 745 750 CGC TTT CTA GAG GAC GAT ACC TCA GAC CCC ACC TAC ACC AGT GCC CTG 2304 Arg Phe Leu Glu Asp Asp Thr Ser Asp Pro Thr Tyr Thr Ser Ala Leu 755 760 765 GGC GGA AAG TTC CCC ATC CGC TGG ACA GCC CCG GAA GCC ATC CAG TAC 2352 Gly Gly Lys Phe Pro He Arg Trp Thr Ala Pro Glu Ala He Gin Tyr 770 775 780 CGG AAG TTC ACC TCG GCC AGT GAT GTG TGG AGC TAC GGC ATT GTC ATG 2400 Arg Lys Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Met 785 790 795 800 TGG GAG GTG ATG TCC TAT GGG GAG CGG CCC TAC TGG GAC ATG ACC AAC 2448 Trp Glu Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Thr Asn 805 810 815 CAG GAT GTA ATC AAT GCC ATT GAG CAG GAC TAT CGG CTG CCA CCG CCC 2496 Gin Asp Val He Asn Ala He Glu Gin Asp Tyr Arg Leu Pro Pro Pro 820 825 830 ATG GAC TGC CCG AGC GCC CTG CAC CAA CTC ATG CTG GAC TGT TGG CAG 2544 Met Asp Cys Pro Ser Ala Leu His Gin Leu Met Leu Asp Cys Trp Gin 835 840 845 AAG GAC CGC AAC CAC CGG CCC AAG TTC GGC CAA ATT GTC AAC ACG CTA 2592 Lys Asp Arg Asn His Arg Pro Lys Phe Gly Gin He Val Asn Thr Leu 850 855 860 GAC AAG ATG ATC CGC AAT CCC AAC AGC CTC AAA GCC ATG GCG CCC CTC 2640 Asp Lys Met He Arg Asn Pro Asn Ser Leu Lys Ala Met Ala Pro Leu 865 870 875 880 TCC TCT GGC ATC AAC CTG CCG CTG CTG GAC CGC ACG ATC CCC GAC TAC 2688 Ser Ser Gly He Asn Leu Pro Leu Leu Asp Arg Thr He Pro Asp Tyr 885 890 895 ACC AGC TTT AAC ACG GTG GAC GAG TGG CTG GAG GCC ATC AAG ATG GGG 2736 Thr Ser Phe Asn Thr Val Asp Glu Trp Leu Glu Ala He Lys Met Gly 900 905 910 CAG TAC AAG GAG AGC TTC GCC AAT GCC GGC TTC ACC TCC TTT GAC GTC 2784 Gin Tyr Lys Glu Ser Phe Ala Asn Ala Gly Phe Thr Ser Phe Asp Val 915 920 925 GTG TCT CAG ATG ATG ATG GAG GAC ATT CTC CGG GTT GGG GTC ACT TTG 2832 Val Ser Gin Met Met Met Glu Asp He Leu Arg Val Gly Val Thr Leu 930 935 940 GCT GGC CAC CAG AAA AAA ATC CTG AAC AGT ATC CAG GTG ATG CGG GCG 2880 Ala Gly His Gin Lys Lys He Leu Asn Ser He Gin Val Met Arg Ala 945 950 955 960 CAG ATG AAC CAG ATT CAG TCT GTG GAG GTT TGACATTCAC CTGCCTCGGC 2930 Gin Met Asn Gin He Gin Ser Val Glu Val 965 970 TCACCTCTTC CTCCAAGCCC CGCCCCCTCT GC 2962 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 970 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Leu Leu Ala Ala Val Glu Glu Thr Leu Met Asp Ser Thr Thr Ala Thr 1 5 10 15 Ala Glu Leu Gly Trp Met Val His Pro Pro Ser Gly Trp Glu Glu Val 20 25 30 Ser Gly Tyr Asp Glu Asn Met Asn Thr He Arg Thr Tyr Gin Val Cys 35 40 45 Asn Val Phe Glu Ser Ser Gin Asn Asn Trp Leu Arg Thr Lys Phe He 50 55 60 Arg Arg Arg Gly Ala His Arg He His Val Glu Met Lys Phe Ser Val 65 70 75 80 Arg Asp Cys Ser Ser He Pro Ser Val Pro Gly Ser Cys Lys Glu Thr 85 90 95 Phe Asn Leu Tyr Tyr Tyr Glu Ala Asp Phe Asp Ser Ala Thr Lys Thr 100 105 110 Phe Pro Asn Trp Met Glu Asn Pro Trp Val Lys Val Asp Thr He Ala 115 120 125 Ala Asp Glu Ser Phe Ser Gin Val Asp Leu Gly Gly Arg Val Met Lys 130 135 140 He Asn Thr Glu Val Arg Ser Phe Gly Pro Val Ser Arg Ser Gly Phe 145 150 155 160 Tyr Leu Ala Phe Gin Asp Tyr Gly Gly Cys Met Ser Leu He Ala Val 165 170 175 Arg Val Phe Tyr Arg Lys Cys Pro Arg He He Gin Asn Gly Ala He 180 185 190 Phe Gin Glu Thr Leu Ser Gly Ala Glu Ser Thr Ser Leu Val Ala Ala 195 200 205 Arg Gly Ser Cys He Ala Asn Ala Glu Glu Val Asp Val Pro He Lys 210 215 220 Leu Tyr Cys Asn Gly Asp Gly Glu Trp Leu Val Pro He Gly Arg Cys 225 230 235 240 Met Cys Lys Ala Gly Phe Glu Ala Val Glu Asn Gly Thr Val Cys Arg 245 250 255 Gly Cys Pro Ser Gly Thr Phe Lys Ala Asn Gin Gly Asp Glu Ala Cys 260 265 270 Thr His Cys Pro He Asn Ser Arg Thr Thr Ser Glu Gly Ala Thr Asn 275 280 285 O 95/28484 - 47 - Cys Val Cys Arg Asn Gly Tyr Tyr Arg Ala Asp Leu Asp Pro Leu Asp 290 295 300 Met Pro Cys Thr Thr He Pro Ser Ala Pro Gin Ala Val He Ser Ser 305 310 315 320 Val Asn Glu Thr Ser Leu Met Leu Glu Trp Thr Pro Pro Arg Asp Ser 325 330 335 Gly Gly Arg Glu Asp Leu Val Tyr Asn He He Cys Lys Ser Cys Gly 340 345 350 Ser Gly Arg Gly Ala Cys Thr Arg Cys Gly Asp Asn Val Gin Tyr Ala 355 360 365 Pro Arg Gin Leu Gly Leu Thr Glu Pro Arg He Tyr He Ser Asp Leu 370 375 380 Leu Ala His Thr Gin Tyr Thr Phe Glu He Gin Ala Val Asn Gly Val 385 390 395 400 Thr Asp Gin Ser Pro Phe Ser Pro Gin Phe Ala Ser Val Asn He Thr 405 410 415 Thr Asn Gin Ala Ala Pro Ser Ala Val Ser He Met His Gin Val Ser 420 425 430 Arg Thr Val Asp Ser He Thr Leu Ser Trp Ser Gin Pro Asp Gin Pro 435 440 445 Asn Gly Val He Leu Asp Tyr Glu Leu Gin Tyr Tyr Glu Lys Glu Leu 450 455 460 Ser Glu Tyr Asn Ala Thr Ala He Lys Ser Pro Thr Asn Thr Val Thr 465 470 475 480 Gly Leu Lys Ala Gly Ala He Tyr Val Phe Gin Val Arg Ala Arg Thr 485 490 495 Val Ala Gly Tyr Gly Arg Tyr Ser Gly Lys Met Tyr Phe Gin Thr Met 500 505 510 Thr Glu Ala Glu Tyr Gin Thr Ser He Gin Glu Lys Leu Pro Leu He 515 520 525 He Gly Ser Ser Ala Ala Gly Leu Val Phe Leu He Ala Val Val Val 530 535 540 He Ala He Val Cys Asn Arg Arg Gly Phe Glu Arg Ala Asp Ser Glu 545 550 555 560 Tyr Thr Asp Lys Leu Gin His Tyr Thr Ser Gly His He Thr Pro Gly 565 570 575 Met Lys He Tyr He Asp Pro Phe Thr Tyr Glu Asp Pro Asn Glu Ala 580 585 590 Val Arg Glu Phe Ala Lys Glu He Asp He Ser Cys Val Lys He Glu 595 600 605 Gin Val He Gly Ala Gly Glu Phe Gly Glu Val Cys Ser Gly His Leu 610 615 620 Lys Leu Pro Gly Lys Arg Glu He Phe Val Ala He Lys Thr Leu Lys 625 630 635 640 Ser Gly Tyr Thr Glu Lys Gin Arg Arg Asp Phe Leu Ser Glu Ala Ser 645 650 655 He Met Gly Gin Phe Asp His Pro Asn Val He His Leu Glu Gly Val 660 665 670 Val Thr Lys Ser Thr Pro Val Met He He Thr Glu Phe Met Glu Asn 675 680 685 Gly Ser Leu Asp Ser Phe Leu Arg Gin Asn Asp Gly Gin Phe Thr Val 690 695 700 He Gin Leu Val Gly Met Leu Arg Gly He Ala Ala Gly Met Lys Tyr 705 710 715 720 Leu Ala Asp Met Asn Tyr Val His Arg Asp Leu Ala Ala Arg Asn He 725 730 735 Leu Val Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser 740 745 750 Arg Phe Leu Glu Asp Asp Thr Ser Asp Pro Thr Tyr Thr Ser Ala Leu 755 760 765 Gly Gly Lys Phe Pro He Arg Trp Thr Ala Pro Glu Ala He Gin Tyr 770 775 780 Arg Lys Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Met 785 790 795 800 Trp Glu Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Thr Asn 805 810 815 Gin Asp Val He Asn Ala He Glu Gin Asp Tyr Arg Leu Pro Pro Pro 820 825 830 Met Asp Cys Pro Ser Ala Leu His Gin Leu Met Leu Asp Cys Trp Gin 835 840 845 Lys Asp Arg Asn His Arg Pro Lys Phe Gly Gin He Val Asn Thr Leu 850 855 860 Asp Lys Met He Arg Asn Pro Asn Ser Leu Lys Ala Met Ala Pro Leu 865 870 875 880 Ser Ser Gly He Asn Leu Pro Leu Leu Asp Arg Thr He Pro Asp Tyr 885 890 895 - 49 - Thr Ser Phe Asn Thr Val Asp Glu Trp Leu Glu Ala He Lys Met Gly 900 905 910 Gin Tyr Lys Glu Ser Phe Ala Asn Ala Gly Phe Thr Ser Phe Asp Val 915 920 925 Val Ser Gin Met Met Met Glu Asp He Leu Arg Val Gly Val Thr Leu 930 935 940 Ala Gly His Gin Lys Lys He Leu Asn Ser He Gin Val Met Arg Ala 945 950 955 960 Gin Met Asn Gin He Gin Ser Val Glu Val 965 970 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3162 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2976 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CCA GCG TCC CTG GCC GGC TGC TAC TCT GCA CCT CGA CGG GCT CCC CTC 48 Pro Ala Ser Leu Ala Gly Cys Tyr Ser Ala Pro Arg Arg Ala Pro Leu 1 5 10 15 TGG ACG TGC CTT CTC CTG TGC GCC GCA CTC CGG ACC CTC CTG GCC AGC 96 Trp Thr Cys Leu Leu Leu Cys Ala Ala Leu Arg Thr Leu Leu Ala Ser 20 25 30 CCC AGC AAC GAA GTG AAT TTA TTG GAT TCA CGC ACT GTC ATG GGG GAC 144 Pro Ser Asn Glu Val Asn Leu Leu Asp Ser Arg Thr Val Met Gly Asp 35 40 45 CTG GGA TGG ATT GCT TTT CCA AAA AAT GGG TGG GAA GAG ATT GGT GAA 192 Leu Gly Trp He Ala Phe Pro Lys Asn Gly Trp Glu Glu He Gly Glu 50 55 60 GTG GAT GAA AAT TAT GCC CCT ATC CAC ACA TAC CAA GTA TGC AAA GTG 240 Val Asp Glu Asn Tyr Ala Pro He His Thr Tyr Gin Val Cys Lys Val 65 70 75 80 ATG GAA CAG AAT CAG AAT AAC TGG CTT TTG ACC AGT TGG ATC TCC AAT 288 Met Glu Gin Asn Gin Asn Asn Trp Leu Leu Thr Ser Trp He Ser Asn 85 90 95 GAA GGT GCT TCC AGA ATC TTC ATA GAA CTC AAA TTT ACC CTG CGG GAC 336 Glu Gly Ala Ser Arg He Phe He Glu Leu Lys Phe Thr Leu Arg Asp 100 105 110 TGC AAC AGC CTT CCT GGA GGA CTG GGG ACC TGT AAG GAA ACC TTT AAT 384 Cys Asn Ser Leu Pro Gly Gly Leu Gly Thr Cys Lys Glu Thr Phe Asn 115 120 125 ATG TAT TAC TTT GAG TCA GAT GAT CAG AAT GGG AGA AAC ATC AAG GAA 432 Met Tyr Tyr Phe Glu Ser Asp Asp Gin Asn Gly Arg Asn He Lys Glu 130 135 140 AAC CAA TAC ATC AAA ATT GAT ACC ATT GCT GCC- GAT GAA AGC TTT ACA 480 Asn Gin Tyr He Lys He Asp Thr He Ala Ala Asp Glu Ser Phe Thr 145 150 155 160 GAA CTT GAT CTT GGT GAC CGT GTT ATG AAA CTG AAT ACA GAG GTC AGA 528 Glu Leu Asp Leu Gly Asp Arg Val Met Lys Leu Asn Thr Glu Val Arg 165 170 175 GAT GTA GGA CCT CTA AGC AAA AAG GGA TTT TAT CTT GCT TTT CAA GAT 576 Asp Val Gly Pro Leu Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gin Asp 180 185 190 GTT GGT GCT TGC ATT GCT CTG GTT TCT GTG CGT GTA TAC TAT AAA AAA 624 Val Gly Ala Cys He Ala Leu Val Ser Val Arg Val Tyr Tyr Lys Lys 195 200 205 TGC CCT TCT GTG GTA CGA CAC TTG GCT GTC TTC CCT GAC ACC ATC ACT 672 Cys Pro Ser Val Val Arg His Leu Ala Val Phe Pro Asp Thr He Thr 210 215 220 GGA GCT GAT TCT TCC CAA TTG CTC GAA GTG TCG GGC TCC TGT GTC AAC 720 Gly Ala Asp Ser Ser Gin Leu Leu Glu Val Ser Gly Ser Cys Val Asn 225 230 235 240 CAT TCT GTG ACC GAT GAA CCT CCC AAA ATG CAC TGC AGC GCC GAA GGG 768 His Ser Val Thr Asp Glu Pro Pro Lys Met His Cys Ser Ala Glu Gly 245 250 255 GAG TGG CTG GTG CCC ATC GGG AAA TGC ATG TGC AAG GCA GGA TAT GAA 816 Glu Trp Leu Val Pro He Gly Lys Cys Met Cys Lys Ala Gly Tyr Glu 260 265 270 GAG AAA AAT GGC ACC TGT CAA GTG TGC AGA CCT GGG TTC TTC AAA GCC 864 Glu Lys Asn Gly Thr Cys Gin Val Cys Arg Pro Gly Phe Phe Lys Ala 275 280 285 TCA CCT CAC ATC CAG AGC TGC GGC AAA TGT CCA CCT CAC AGT TAT ACC 912 Ser Pro His He Gin Ser Cys Gly Lys Cys Pro Pro His Ser Tyr Thr 290 295 300 CAT GAG GAA GCT TCA ACC TCT TGT GTC TGT GAA AAG GAT TAT TTC AGG 960 His Glu Glu Ala Ser Thr Ser Cys Val Cys Glu Lys Asp Tyr Phe Arg 305 310 315 320 AGA GAG TCT GAT CCA CCC ACA ATG GCA TGC ACA AGA CCC CCC TCT GCT 1008 Arg Glu Ser Asp Pro Pro Thr Met Ala Cys Thr Arg Pro Pro Ser Ala 325 330 335 CCT CGG AAT GCC ATC TCA AAT GTT AAT GAA ACT AGT GTC TTT CTG GAA 1056 Pro Arg Asn Ala He Ser Asn Val Asn Glu Thr Ser Val Phe Leu Glu 340 345 350 TGG ATT CCG CCT GCT GAC ACT GGT GGA AGG AAA GAC GTG TCA TAT TAT 1104 Trp He Pro Pro Ala Asp Thr Gly Gly Arg Lys Asp Val Ser Tyr Tyr 355 360 365 ATT GCA TGC AAG AAG TGC AAC TCC CAT GCA GGT GTG TGT GAG GAG TGT 1152 He Ala Cys Lys Lys Cys Asn Ser His Ala Gly Val Cys Glu Glu Cys 370 375 380 GGC GGT CAT GTC AGG TAC CTT CCC CGG CAA AGC GGC CTG AAA AAC ACC 1200 Gly Gly His Val Arg Tyr Leu Pro Arg Gin Ser Gly Leu Lys Asn Thr 385 390 395 400 TCT GTC ATG ATG GTG GAT CTA CTC GCT CAC ACA AAC TAT ACC TTT GAG 1248 Ser Val Met Met Val Asp Leu Leu Ala His Thr Asn Tyr Thr Phe Glu 405 410 415 ATT GAG GCA GTG AAT GGA GTG TCC GAC TTG AGC CCA GGA GCC CGG CAG 1296 He Glu Ala Val Asn Gly Val Ser Asp Leu Ser Pro Gly Ala Arg Gin 420 425 430 TAT GTG TCT GTA AAT GTA ACC ACA AAT CAA GCA GCT CCA TCT CCA GTC 1344 Tyr Val Ser Val Asn Val Thr Thr Asn Gin Ala Ala Pro Ser Pro Val 435 440 445 ACC AAT GTG AAA AAA GGG AAA ATT GCA AAA AAC AGC ATC TCT TTG TCT 1392 Thr Asn Val Lys Lys Gly Lys He Ala Lys Asn Ser He Ser Leu Ser 450 455 460 TGG CAA GAA CCA GAT CGT CCC AAT GGA ATC ATC CTA GAG TAT GAA ATC 1440 Trp Gin Glu Pro Asp Arg Pro Asn Gly He He Leu Glu Tyr Glu He 465 470 475 480 AAG CAT TTT GAA AAG GAC CAA GAG ACC AGC TAC ACG ATT ATC AAA TCT 1488 Lys His Phe Glu Lys Asp Gin Glu Thr Ser Tyr Thr He He Lys Ser 485 490 495 AAA GAG ACA ACT ATT ACT GCA GAG GGC TTG AAA CCA GCT TCA GTT TAT 1536 Lys Glu Thr Thr He Thr Ala Glu Gly Leu Lys Pro Ala Ser Val Tyr 500 505 510 GTC TTC CAA ATT CGA GCA CGT ACA GCA GCA GGC TAT GGT GTC TTC AGT 1584 Val Phe Gin He Arg Ala Arg Thr Ala Ala Gly Tyr Gly Val Phe Ser 515 520 525 CGA AGA TTT GAG TTT GAA ACC ACC CCA GTG TTT GCA GCA TCC AGC GAT 1632 Arg Arg Phe Glu Phe Glu Thr Thr Pro Val Phe Ala Ala Ser Ser Asp 530 535 540 CAA AGC CAG ATT CCT GTA ATT GCT GTG TCT GTG ACA GTA GGA GTC ATT 1680 Gin Ser Gin He Pro Val He Ala Val Ser Val Thr Val Gly Val He 545 550 555 560 TTG TTG GCA GTG GTT ATC GGC GTC CTC CTC AGT GGA AGG CGG TGT GGC 1728 Leu Leu Ala Val Val He Gly Val Leu Leu Ser Gly Arg Arg Cys Gly 565 570 575 TAC AGC AAA GCA AAA CAA GAT CCA GAA GAG GAA AAG ATG CAT TTT CAT 1776 Tyr Ser Lys Ala Lys Gin Asp Pro Glu Glu Glu Lys Met His Phe His 580 585 590 AAT GGG CAC ATT AAA CTG CCA GGA GTA AGA ACT TAC ATT GAT CCA CAT 1824 Asn Gly His He Lys Leu Pro Gly Val Arg Thr Tyr He Asp Pro His 595 600 605 ACC TAT GAG GAT CCC AAT CAA GCT GTC CAC GAA TTT GCC AAG GAG ATA 1872 Thr Tyr Glu Asp Pro Asn Gin Ala Val His Glu Phe Ala Lys Glu He 610 615 620 GAA GCA TCA TGT ATC ACC ATT GAG AGA GTT ATT GGA GCA GGT GAA TTT 1920 Glu Ala Ser Cys He Thr He Glu Arg Val He Gly Ala Gly Glu Phe 625 630 635 640 GGT GAA GTT TGT AGT GGA CGT TTG AAA CTA CCA GGA AAA AGA GAA TTA 1968 Gly Glu Val Cys Ser Gly Arg Leu Lys Leu Pro Gly Lys Arg Glu Leu 645 650 655 CCT GTG GCT ATC AAA ACC CTT AAA GTA GGC TAT ACT GAA AAG CAA CGC 2016 Pro Val Ala He Lys Thr Leu Lys Val Gly Tyr Thr Glu Lys Gin Arg 660 665 670 AGA GAT TTC CTA GGT GAA GCA AGT ATC ATG GGA CAG TTT GAT CAT CCT 2064 Arg Asp Phe Leu Gly Glu Ala Ser He Met Gly Gin Phe Asp His Pro 675 680 685 AAC ATC ATC CAT TTA GAA GGT GTG GTG ACC AAA AGT AAA CCA GTG ATG 2112 Asn He He His Leu Glu Gly Val Val Thr Lys Ser Lys Pro Val Met 690 695 700 ATC GTG ACA GAG TAT ATG GAG AAT GGC TCT TTA GAT ACA TTT TTG AAG 2160 He Val Thr Glu Tyr Met Glu Asn Gly Ser Leu Asp Thr Phe Leu Lys 705 710 715 720 AAA AAC GAT GGG CAG TTC ACT GTG ATT CAG CTT GTT GGC ATG CTG AGA 2208 Lys Asn Asp Gly Gin Phe Thr Val He Gin Leu Val Gly Met Leu Arg 725 730 735 GGT ATC TCT GCA GGA ATG AAG TAC CTT TCT GAC ATG GGC TAT GTG CAT 2256 Gly He Ser Ala Gly Met Lys Tyr Leu Ser Asp Met Gly Tyr Val His 740 745 750 AGA GAT CTT GCT GCC AGA AAC ATC TTA ATC AAC AGT AAC CTT GTG TGC 2304 Arg Asp Leu Ala Ala Arg Asn He Leu He Asn Ser Asn Leu Val Cys 755 760 765 AAA GTG TCT GAC TTT GGA CTT TCC CGG GTA CTG GAA GAT GAT CCC GAG 2352 Lys Val Ser Asp Phe Gly Leu Ser Arg Val Leu Glu Asp Asp Pro Glu 770 775 780 GCA GCC TAC ACC ACA AGG GGA GGA AAA ATT CCA ATC AGA TGG ACT GCC 2400 Ala Ala Tyr Thr Thr Arg Gly Gly Lys He Pro He Arg Trp Thr Ala 785 790 795 800 CCA GAA GCA ATA GCT TTC CGA AAG TTT ACT TCT GCC AGT GAT GTC TGG 2448 Pro Glu Ala He Ala Phe Arg Lys Phe Thr Ser Ala Ser Asp Val Trp 805 810 815 AGT TAT GGA ATA GTA ATG TGG GAA GTT GTG TCT TAT GGA GAG AGA CCC 2496 Ser Tyr Gly He Val Met Trp Glu Val Val Ser Tyr Gly Glu Arg Pro 820 825 830 TAC TGG GAG ATG ACC AAT CAA GAT GTG ATT AAA GCG GTA GAG GAA GGC 2544 Tyr Trp Glu Met Thr Asn Gin Asp Val He Lys Ala Val Glu Glu Gly 835 840 845 TAT CGT CTG CCA AGC CCC ATG GAT TGT CCT GCT GCT CTC TAT CAG TTA 2592 Tyr Arg Leu Pro Ser Pro Met Asp Cys Pro Ala Ala Leu Tyr Gin Leu 850 855 860 ATG CTG GAT TGC TGG CAG AAA GAG CGA AAT AGC AGG CCC AAG TTT GAT 2640 Met Leu Asp Cys Trp Gin Lys Glu Arg Asn Ser Arg Pro Lys Phe Asp 865 870 875 880 GAA ATA GTC AAC ATG TTG GAC AAG CTG ATA CGT AAC CCA AGT AGT CTG 2688 Glu He Val Asn Met Leu Asp Lys Leu He Arg Asn Pro Ser Ser Leu 885 890 895 AAG ACG CTG GTT AAT GCA TCC TGC AGA GTA TCT AAT TTA TTG GCA GAA 2736 Lys Thr Leu Val Asn Ala Ser Cys Arg Val Ser Asn Leu Leu Ala Glu 900 905 910 CAT AGC CCA CTA GGA TCT GGG GCC TAC AGA TCA GTA GGT GAA TGG CTA 2784 His Ser Pro Leu Gly Ser Gly Ala Tyr Arg Ser Val Gly Glu Trp Leu 915 920 925 GAG GCA ATC AAG ATG GGC CGG TAT ACA GAG ATT TTC ATG GAA AAT GGA 2832 Glu Ala He Lys Met Gly Arg Tyr Thr Glu He Phe Met Glu Asn Gly 930 935 940 TAC AGT TCA ATG GAC GCT GTG GCT CAG GTG ACC TTG GAG GAT TTG AGA 2880 Tyr Ser Ser Met Asp Ala Val Ala Gin Val Thr Leu Glu Asp Leu Arg 945 950 955 960 CGG CTT GGA GTG ACT CTT GTC GGT CAC CAG AAG AAG ATC ATG AAC AGC 2928 Arg Leu Gly Val Thr Leu Val Gly His Gin Lys Lys He Met Asn Ser 965 970 975 CTT CAA GAA ATG AAG GTG CAG CTG GTA AAC GGA ATG GTG CCA TTG TAACTTCATG 2983 Leu Gin Glu Met Lys Val Gin Leu Val Asn Gly Met Val Pro Leu 980 985 990 TAAATGTCGC TTCTTCAAGT GAATGATTCT GCACTTTGTA AACAGCACTG AGATTTATTT 3043 TAACAAAAAA AGGGGGAAAA GGGAAAACAG TGATTTCTAA ACCTTAGAAA ACATTTGCCT 3103 CAGCCACAGA ATTTGTAATC ATGGTTTTAC TGAAGTATCC AGTTCTTAGT CCTTAGTCT 3162 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 991 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Pro Ala Ser Leu Ala Gly Cys Tyr Ser Ala Pro Arg Arg Ala Pro Leu 1 5 10 15 Trp Thr Cys Leu Leu Leu Cys Ala Ala Leu Arg Thr Leu Leu Ala Ser 20 25 30 Pro Ser Asn Glu Val Asn Leu Leu Asp Ser Arg Thr Val Met Gly Asp 35 40 45 Leu Gly Trp He Ala Phe Pro Lys Asn Gly Trp Glu Glu He Gly Glu 50 55 60 Val Asp Glu Asn Tyr Ala Pro He His Thr Tyr Gin Val Cys Lys Val 65 70 75 80 Met Glu Gin Asn Gin Asn Asn Trp Leu Leu Thr Ser Trp He Ser Asn 85 90 95 Glu Gly Ala Ser Arg He Phe He Glu Leu Lys Phe Thr Leu Arg Asp 100 105 110 Cys Asn Ser Leu Pro Gly Gly Leu Gly Thr Cys Lys Glu Thr Phe Asn 115 120 125 Met Tyr Tyr Phe Glu Ser Asp Asp Gin Asn Gly Arg Asn He Lys Glu 130 135 140 Asn Gin Tyr He Lys He Asp Thr He Ala Ala Asp Glu Ser Phe Thr 145 150 155 160 Glu Leu Asp Leu Gly Asp Arg Val Met Lys Leu Asn Thr Glu Val Arg 165 170 175 Asp Val Gly Pro Leu Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gin Asp 180 185 190 Val Gly Ala Cys He Ala Leu Val Ser Val Arg Val Tyr Tyr Lys Lys 195 200 205 Cys Pro Ser Val Val Arg His Leu Ala Val Phe Pro Asp Thr He Thr 210 215 220 Gly Ala Asp Ser Ser Gin Leu Leu Glu Val Ser Gly Ser Cys Val Asn 225 230 235 240 His Ser Val Thr Asp Glu Pro Pro Lys Met His Cys Ser Ala Glu Gly 245 250 255 Glu Trp Leu Val Pro He Gly Lys Cys Met Cys Lys Ala Gly Tyr Glu 260 265 270 Glu Lys Asn Gly Thr Cys Gin Val Cys Arg Pro Gly Phe Phe Lys Ala 275 280 285 Ser Pro His He Gin Ser Cys Gly Lys Cys Pro Pro His Ser Tyr Thr 290 295 300 His Glu Glu Ala Ser Thr Ser Cys Val Cys Glu Lys Asp Tyr Phe Arg 305 310 315 320 Arg Glu Ser Asp Pro Pro Thr Met Ala Cys Thr Arg Pro Pro Ser Ala 325 330 335 Pro Arg Asn Ala He Ser Asn Val Asn Glu Thr Ser Val Phe Leu Glu 340 345 350 Trp He Pro Pro Ala Asp Thr Gly Gly Arg Lys Asp Val Ser Tyr Tyr 355 360 365 He Ala Cys Lys Lys Cys Asn Ser His Ala Gly Val Cys Glu Glu Cys 370 375 380 Gly Gly His Val Arg Tyr Leu Pro Arg Gin Ser Gly Leu Lys Asn Thr 385 390 395 400 Ser Val Met Met Val Asp Leu Leu Ala His Thr Asn Tyr Thr Phe Glu 405 410 415 He Glu Ala Val Asn Gly Val Ser Asp Leu Ser Pro Gly Ala Arg Gin 420 425 430 Tyr Val Ser Val Asn Val Thr Thr Asn Gin Ala Ala Pro Ser Pro Val 435 440 445 Thr Asn Val Lys Lys Gly Lys He Ala Lys Asn Ser He Ser Leu Ser 450 455 460 Trp Gin Glu Pro Asp Arg Pro Asn Gly He He Leu Glu Tyr Glu He 465 470 475 480 Lys His Phe Glu Lys Asp Gin Glu Thr Ser Tyr Thr He He Lys Ser 485 490 495 Lys Glu Thr Thr He Thr Ala Glu Gly Leu Lys Pro Ala Ser Val Tyr 500 505 510 Val Phe Gin He Arg Ala Arg Thr Ala Ala Gly Tyr Gly Val Phe Ser 515 520 525 - 56 - Arg Arg Phe Glu Phe Glu Thr Thr Pro Val Phe Ala Ala Ser Ser Asp 530 535 540 Gin Ser Gin He Pro Val He Ala Val Ser Val Thr Val Gly Val He 545 550 555 560 Leu Leu Ala Val Val He Gly Val Leu Leu Ser Gly Arg Arg Cys Gly 565 570 575 Tyr Ser Lys Ala Lys Gin Asp Pro Glu Glu Glu Lys Met His Phe His 580 585 590 Asn Gly His He Lys Leu Pro Gly Val Arg Thr Tyr He Asp Pro His 595 600 605 Thr Tyr Glu Asp Pro Asn Gin Ala Val His Glu Phe Ala Lys Glu He 610 615 620 Glu Ala Ser Cys He Thr He Glu Arg Val He Gly Ala Gly Glu Phe 625 630 635 640 Gly Glu Val Cys Ser Gly Arg Leu Lys Leu Pro Gly Lys Arg Glu Leu 645 650 655 Pro Val Ala He Lys Thr Leu Lys Val Gly Tyr Thr Glu Lys Gin Arg 660 665 670 Arg Asp Phe Leu Gly Glu Ala Ser He Met Gly Gin Phe Asp His Pro 675 680 685 Asn He He His Leu Glu Gly Val Val Thr Lys Ser Lys Pro Val Met 690 695 700 He Val Thr Glu Tyr Met Glu Asn Gly Ser Leu Asp Thr Phe Leu Lys 705 710 715 720 Lys Asn Asp Gly Gin Phe Thr Val He Gin Leu Val Gly Met Leu Arg 725 730 735 Gly He Ser Ala Gly Met Lys Tyr Leu Ser Asp Met Gly Tyr Val His 740 745 750 Arg Asp Leu Ala Ala Arg Asn He Leu He Asn Ser Asn Leu Val Cys 755 760 765 Lys Val Ser Asp Phe Gly Leu Ser Arg Val Leu Glu Asp Asp Pro Glu 770 775 780 Ala Ala Tyr Thr Thr Arg Gly Gly Lys He Pro He Arg Trp Thr Ala 785 790 795 800 Pro Glu Ala He Ala Phe Arg Lys Phe Thr Ser Ala Ser Asp Val Trp 805 810 815 Ser Tyr Gly He Val Met Trp Glu Val Val Ser Tyr Gly Glu Arg Pro 820 825 830 Tyr Trp Glu Met Thr Asn Gin Asp Val He Lys Ala Val Glu Glu Gly 835 840 845 Tyr Arg Leu Pro Ser Pro Met Asp Cys Pro Ala Ala Leu Tyr Gin Leu 850 855 860 Met Leu Asp Cys Trp Gin Lys Glu Arg Asn Ser Arg Pro Lys Phe Asp 865 870 875 880 Glu He Val Asn Met Leu Asp Lys Leu He Arg Asn Pro Ser Ser Leu 885 890 895 Lys Thr Leu Val Asn Ala Ser Cys Arg Val Ser Asn Leu Leu Ala Glu 900 905 910 His Ser Pro Leu Gly Ser Gly Ala Tyr Arg Ser Val Gly Glu Trp Leu 915 920 925 Glu Ala He Lys Met Gly Arg Tyr Thr Glu He Phe Met Glu Asn Gly 930 935 940 Tyr Ser Ser Met Asp Ala Val Ala Gin Val Thr Leu Glu Asp Leu Arg 945 950 955 960 Arg Leu Gly Val Thr Leu Val Gly His Gin Lys Lys He Met Asn Ser 965 970 975 Leu Gin Glu Met Lys Val Gin Leu Val Asn Gly Met Val Pro Leu 980 985 990 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3116 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 34..2994 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AAGCGGCAGG AGCAGCGTTG GCACCGGCGA ACC ATG GCT GGG ATT TTC TAT TTC 54 Met Ala Gly He Phe Tyr Phe 1 5 GCC CTA TTT TCG TGT CTC TTC GGG ATT TGC GAC GCT GTC ACA GGT TCC 102 Ala Leu Phe Ser Cys Leu Phe Gly He Cys Asp Ala Val Thr Gly Ser 10 15 20 AGG GTA TAC CCC GCG AAT GAA GTT ACC TTA TTG GAT TCC AGA TCT GTT 150 Arg Val Tyr Pro Ala Asn Glu Val Thr Leu Leu Asp Ser Arg Ser Val 25 30 35 CAG GGA GAA CTT GGG TGG ATA GCA AGC CCT CTG GAA GGA GGG TGG GAG 198 Gin Gly Glu Leu Gly Trp He Ala Ser Pro Leu Glu Gly Gly Trp Glu 40 45 50 55 GAA GTG AGT ATC ATG GAT GAA AAA AAT ACA CCA ATC CGA ACC TAC CAA 246 Glu Val Ser He Met Asp Glu Lys Asn Thr Pro He Arg Thr Tyr Gin 60 65 70 GTG TGC AAT GTG ATG GAA CCC AGC CAG AAT AAC TGG CTA CGA ACT GAT 294 Val Cys Asn Val Met Glu Pro Ser Gin Asn Asn Trp Leu Arg Thr Asp 75 80 85 TGG ATC ACC CGA GAA GGG GCT CAG AGG GTG TAT ATT GAG ATT AAA TTC 342 Trp He Thr Arg Glu Gly Ala Gin Arg Val Tyr He Glu He Lys Phe 90 95 100 ACC TTG AGG GAC TGC AAT AGT CTT CCG GGC GTC ATG GGG ACT TGC AAG 390 Thr Leu Arg Asp Cys Asn Ser Leu Pro Gly Val Met Gly Thr Cys Lys 105 110 115 GAG ACG TTT AAC CTG TAC TAC TAT GAA TCA GAC AAC GAC AAA GAG CGT 438 Glu Thr Phe Asn Leu Tyr Tyr Tyr Glu Ser Asp Asn Asp Lys Glu Arg 120 125 130 135 TTC ATC AGA GAG AAC CAG TTT GTC AAA ATT GAC ACC ATT GCT GCT GAT 486 Phe He Arg Glu Asn Gin Phe Val Lys He Asp Thr He Ala Ala Asp 140 145 150 GAG AGC TTC ACC CAA GTG GAC ATT GGT GAC AGA ATC ATG AAG CTG AAC 534 Glu Ser Phe Thr Gin Val Asp He Gly Asp Arg He Met Lys Leu Asn 155 160 165 ACC GAG ATC CGG GAT GTA GGG CCA TTA AGC AAA AAG GGG TTT TAC CTG 582 Thr Glu He Arg Asp Val Gly Pro Leu Ser Lys Lys Gly Phe Tyr Leu 170 175 180 GCT TTT CAG GAT GTG GGG GCC TGC ATC GCC CTG GTA TCA GTC CGT GTG 630 Ala Phe Gin Asp Val Gly Ala Cys He Ala Leu Val Ser Val Arg Val 185 190 195 TTC TAT AAA AAG TGT CCA CTC ACA GTC CGC AAT CTG GCC CAG TTT CCT 678 Phe Tyr Lys Lys Cys Pro Leu Thr Val Arg Asn Leu Ala Gin Phe Pro 200 205 210 215 GAC ACC ATC ACA GGG GCT GAT ACG TCT TCC CTG GTG GAA GTT CGA GGC 726 Asp Thr He Thr Gly Ala Asp Thr Ser Ser Leu Val Glu Val Arg Gly 220 225 230 TCC TGT GTC AAC AAC TCA GAA GAG AAA GAT GTG CCA AAA ATG TAC TGT 774 Ser Cys Val Asn Asn Ser Glu Glu Lys Asp Val Pro Lys Met Tyr Cys 235 240 245 - 59 - GGG GCA GAT GGT GAA TGG CTG GTA CCC ATT GGC AAC TGC CTA TGC AAC 822 Gly Ala Asp Gly Glu Trp Leu Val Pro He Gly Asn Cys Leu Cys Asn 250 255 260 GCT GGG CAT GAG GAG CGG AGC GGA GAA TGC CAA GCT TGC AAA ATT GGA 870 Ala Gly His Glu Glu Arg Ser Gly Glu Cys Gin Ala Cys Lys He Gly 265 270 275 TAT TAC AAG GCT CTC TCC ACG GAT GCC ACC TGT GCC AAG TGC CCA CCC 918 Tyr Tyr Lys Ala Leu Ser Thr Asp Ala Thr Cys Ala Lys Cys Pro Pro 280 285 290 295 CAC AGC TAC TCT GTC TGG GAA GGA GCC ACC TCG TGC ACC TGT GAC CGA 966 His Ser Tyr Ser Val Trp Glu Gly Ala Thr Ser Cys Thr Cys Asp Arg 300 305 310 GGC TTT TTC AGA GCT GAC AAC GAT GCT GCC TCT ATG CCC TGC ACC CGT 1014 Gly Phe Phe Arg Ala Asp Asn Asp Ala Ala Ser Met Pro Cys Thr Arg 315 320 325 CCA CCA TCT GCT CCC CTG AAC TTG ATT TCA AAT GTC AAC GAG ACA TCT 1062 Pro Pro Ser Ala Pro Leu Asn Leu He Ser Asn Val Asn Glu Thr Ser 330 335 340 GTG AAC TTG GAA TGG AGT AGC CCT CAG AAT ACA GGT GGC CGC CAG GAC 1110 Val Asn Leu Glu Trp Ser Ser Pro Gin Asn Thr Gly Gly Arg Gin Asp 345 350 355 ATT TCC TAT AAT GTG GTA TGC AAG AAA TGT GGA GCT GGT GAC CCC AGC 1158 He Ser Tyr Asn Val Val Cys Lys Lys Cys Gly Ala Gly Asp Pro Ser 360 365 370 375 AAG TGC CGA CCC TGT GGA AGT GGG GTC CAC TAC ACC CCA CAG CAG AAT 1206 Lys Cys Arg Pro Cys Gly Ser Gly Val His Tyr Thr Pro Gin Gin Asn 380 385 390 GGC TTG AAG ACC ACC AAA GTC TCC ATC ACT GAC CTC CTA GCT CAT ACC 1254 Gly Leu Lys Thr Thr Lys Val Ser He Thr Asp Leu Leu Ala His Thr 395 400 405 AAT TAC ACC TTT GAA ATC TGG GCT GTG AAT GGA GTG TCC AAA TAT AAC 1302 Asn Tyr Thr Phe Glu He Trp Ala Val Asn Gly Val Ser Lys Tyr Asn 410 415 420 CCT AAC CCA GAC CAA TCA GTT TCT GTC ACT GTG ACC ACC AAC CAA GCA 1350 Pro Asn Pro Asp Gin Ser Val Ser Val Thr Val Thr Thr Asn Gin Ala 425 430 435 GCA CCA TCA TCC ATT GCT TTG GTC CAG GCT AAA GAA GTC ACA AGA TAC 1398 Ala Pro Ser Ser He Ala Leu Val Gin Ala Lys Glu Val Thr Arg Tyr 440 445 450 455 AGT GTG GCA CTG GCT TGG CTG GAA CCA GAT CGG CCC AAT GGG GTA ATC 1446 Ser Val Ala Leu Ala Trp Leu Glu Pro Asp Arg Pro Asn Gly Val He 460 465 470 CTG GAA TAT GAA GTC AAG TAT TAT GAG AAG GAT CAG AAT GAG CGA AGC 1494 Leu Glu Tyr Glu Val Lys Tyr Tyr Glu Lys Asp Gin Asn Glu Arg Ser 475 480 485 TAT CGT ATA GTT CGG ACA GCT GCC AGG AAC ACA GAT ATC AAA GGC CTG 1542 Tyr Arg He Val Arg Thr Ala Ala Arg Asn Thr Asp He Lys Gly Leu 490 495 500 AAC CCT CTC ACT TCC TAT GTT TTC CAC GTG CGA GCC AGG ACA GCA GCT 1590 Asn Pro Leu Thr Ser Tyr Val Phe His Val Arg Ala Arg Thr Ala Ala 505 510 515 GGC TAT GGA GAC TTC AGT GAG CCC TTG GAG GTT ACA ACC AAC ACA GTG 1638 Gly Tyr Gly Asp Phe Ser Glu Pro Leu Glu Val Thr Thr Asn Thr Val 520 525 530 535 CCT TCC CGG ATC ATT GGA GAT GGG GCT AAC TCC ACA GTC CTT CTG GTC 1686 Pro Ser Arg He He Gly Asp Gly Ala Asn Ser Thr Val Leu Leu Val 540 545 550 TCT GTC TCG GGC AGT GTG GTG CTG GTG GTA ATT CTC ATT GCA GCT TTT 1734 Ser Val Ser Gly Ser Val Val Leu Val Val He Leu He Ala Ala Phe 555 560 565 GTC ATC AGC CGG AGA CGG AGT AAA TAC AGT AAA GCC AAA CAA GAA GCG 1782 Val He Ser Arg Arg Arg Ser Lys Tyr Ser Lys Ala Lys Gin Glu Ala 570 575 580 GAT GAA GAG AAA CAT TTG AAT CAA GGT GTA AGA ACA TAT GTG GAC CCC 1830 Asp Glu Glu Lys His Leu Asn Gin Gly Val Arg Thr Tyr Val Asp Pro 585 590 595 TTT ACG TAC GAA GAT CCC AAC CAA GCA GTG CGA GAG TTT GCC AAA GAA 1878 Phe Thr Tyr Glu Asp Pro Asn Gin Ala Val Arg Glu Phe Ala Lys Glu 600 605 610 615 ATT GAC GCA TCC TGC ATT AAG ATT GAA AAA GTT ATA GGA GTT GGT GAA 1926 He Asp Ala Ser Cys He Lys He Glu Lys Val He Gly Val Gly Glu 620 625 630 TTT GGT GAG GTA TGC AGT GGG CGT CTC AAA GTG CCT GGC AAG AGA GAG 1974 Phe Gly Glu Val Cys Ser Gly Arg Leu Lys Val Pro Gly Lys Arg Glu 635 640 645 ATC TGT GTG GCT ATC AAG ACT CTG AAA GCT GGT TAT ACA GAC AAA CAG 2022 He Cys Val Ala He Lys Thr Leu Lys Ala Gly Tyr Thr Asp Lys Gin 650 655 660 AGG AGA GAC TTC CTG AGT GAG GCC AGC ATC ATG GGA CAG TTT GAC CAT 2070 Arg Arg Asp Phe Leu Ser Glu Ala Ser He Met Gly Gin Phe Asp His 665 670 675 CCG AAC ATC ATT CAC TTG GAA GGC GTG GTC ACT AAA TGT AAA CCA GTA 2118 Pro Asn He He His Leu Glu Gly Val Val Thr Lys Cys Lys Pro Val 680 685 690 695 ATG ATC ATA ACA GAG TAC ATG GAG AAT GGC TCC TTG GAT GCA TTC CTC 2166 Met He He Thr Glu Tyr Met Glu Asn Gly Ser Leu Asp Ala Phe Leu 700 705 710 AGG AAA AAT GAT GGC AGA TTT ACA GTC ATT CAG CTG GTG GGC ATG CTT 2214 Arg Lys Asn Asp Gly Arg Phe Thr Val He Gin Leu Val Gly Met Leu 715 720 725 CGT GGC ATT GGG TCT GGG ATG AAG TAT TTA TCT GAT ATG AGC TAT GTG 2262 Arg Gly He Gly Ser Gly Met Lys Tyr Leu Ser Asp Met Ser Tyr Val 730 735 740 CAT CGT GAT CTG GCC GCA CGG AAC ATC CTG GTG AAC AGC AAC TTG GTC 2310 His Arg Asp Leu Ala Ala Arg Asn He Leu Val Asn Ser Asn Leu Val 745 750 755 TGC AAA GTG TCT GAT TTT GGC ATG TCC CGA GTG CTT GAG GAT GAT CCG 2358 Cys Lys Val Ser Asp Phe Gly Met Ser Arg Val Leu Glu Asp Asp Pro 760 765 770 775 GAA GCA GCT TAC ACC ACC AGG GGT GGC AAG ATT CCT ATC CGG TGG ACT 2406 Glu Ala Ala Tyr Thr Thr Arg Gly Gly Lys He Pro He Arg Trp Thr 780 785 790 GCG CCA GAA GCA ATT GCC TAT CGT AAA TTC ACA TCA GCA AGT GAT GTA 2454 Ala Pro Glu Ala He Ala Tyr Arg Lys Phe Thr Ser Ala Ser Asp Val 795 800 805 TGG AGC TAT GGA ATC GTT ATG TGG GAA GTG ATG TCG TAC GGG GAG AGG 2502 Trp Ser Tyr Gly He Val Met Trp Glu Val Met Ser Tyr Gly Glu Arg 810 815 820 CCC TAT TGG GAT ATG TCC AAT CAA GAT GTG ATT AAA GCC ATT GAG GAA 2550 Pro Tyr Trp Asp Met Ser Asn Gin Asp Val He Lys Ala He Glu Glu 825 830 835 GGC TAT CGG TTA CCC CCT CCA ATG GAC TGC CCC ATT GCG CTC CAC CAG 2598 Gly Tyr Arg Leu Pro Pro Pro Met Asp Cys Pro He Ala Leu His Gin 840 845 850 855 CTG ATG CTA GAC TGC TGG CAG AAG GAG AGG AGC GAC AGG CCT AAA TTT 2646 Leu Met Leu Asp Cys Trp Gin Lys Glu Arg Ser Asp Arg Pro Lys Phe 860 865 870 GGG CAG ATT GTC AAC ATG TTG GAC AAA CTC ATC CGC AAC CCC AAC AGC 2694 Gly Gin He Val Asn Met Leu Asp Lys Leu He Arg Asn Pro Asn Ser 875 880 885 TTG AAG AGG ACA GGG ACG GAG AGC TCC AGA CCT AAC ACT GCC TTG TTG 2742 Leu Lys Arg Thr Gly Thr Glu Ser Ser Arg Pro Asn Thr Ala Leu Leu 890 895 900 GAT CCA AGC TCC CCT GAA TTC TCT GCT GTG GTA TCA GTG GGC GAT TGG 2790 Asp Pro Ser Ser Pro Glu Phe Ser Ala Val Val Ser Val Gly Asp Trp 905 910 915 CTC CAG GCC ATT AAA ATG GAC CGG TAT AAG GAT AAC TTC ACA GCT GCT 2838 Leu Gin Ala He Lys Met Asp Arg Tyr Lys Asp Asn Phe Thr Ala Ala 920 925 930 935 GGT TAT ACC ACA CTA GAG GCT GTG GTG CAC GTG AAC CAG GAG GAC CTG 2886 Gly Tyr Thr Thr Leu Glu Ala Val Val His Val Asn Gin Glu Asp Leu 940 945 950 GCA AGA ATT GGT ATC ACA GCC ATC ACG CAC CAG AAT AAG ATT TTG AGC 2934 Ala Arg He Gly He Thr Ala He Thr His Gin Asn Lys He Leu Ser 955 960 965 AGT GTC CAG GCA ATG CGA ACC CAA ATG CAG CAG ATG CAC GGC AGA ATG 2982 Ser Val Gin Ala Met Arg Thr Gin Met Gin Gin Met His Gly Arg Met 970 975 980 GTT CCC GTC TGAGCCAGTA CTGAATAAAC TCAAAACTCT TGAAATTAGT 3031 Val Pro Val 985 TTACCTCATC CATGCACTTT AATTGAAGAA CTGCACTTTT TTTACTTCGT CTTCGCCCTC 3091 TGAAATTAAA GAAATGAAAA AAAAA 3116 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 986 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Ala Gly He Phe Tyr Phe Ala Leu Phe Ser Cys Leu Phe Gly He 1 5 10 15 Cys Asp Ala Val Thr Gly Ser Arg Val Tyr Pro Ala Asn Glu Val Thr 20 25 30 Leu Leu Asp Ser Arg Ser Val Gin Gly Glu Leu Gly Trp He Ala Ser 35 40 45 Pro Leu Glu Gly Gly Trp Glu Glu Val Ser He Met Asp Glu Lys Asn 50 55 60 Thr Pro He Arg Thr Tyr Gin Val Cys Asn Val Met Glu Pro Ser Gin 65 70 75 80 Asn Asn Trp Leu Arg Thr Asp Trp He Thr Arg Glu Gly Ala Gin Arg 85 90 95 Val Tyr He Glu He Lys Phe Thr Leu Arg Asp Cys Asn Ser Leu Pro 100 105 110 Gly Val Met Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Tyr Glu 115 120 125 Ser Asp Asn Asp Lys Glu Arg Phe He Arg Glu Asn Gin Phe Val Lys 130 135 140 He Asp Thr He Ala Ala Asp Glu Ser Phe Thr Gin Val Asp He Gly 145 150 155 160 Asp Arg He Met Lys Leu Asn Thr Glu He Arg Asp Val Gly Pro Leu 165 170 175 Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gin Asp Val Gly Ala Cys He 180 185 190 Ala Leu Val Ser Val Arg Val Phe Tyr Lys Lys Cys Pro Leu Thr Val 195 200 205 Arg Asn Leu Ala Gin Phe Pro Asp Thr He Thr Gly Ala Asp Thr Ser 210 215 220 Ser Leu Val Glu Val Arg Gly Ser Cys Val Asn Asn Ser Glu Glu Lys 225 230 235 240 Asp Val Pro Lys Met Tyr Cys Gly Ala Asp Gly Glu Trp Leu Val Pro 245 250 255 He Gly Asn Cys Leu Cys Asn Ala Gly His Glu Glu Arg Ser Gly Glu 260 265 270 Cys Gin Ala Cys Lys He Gly Tyr Tyr Lys Ala Leu Ser Thr Asp Ala 275 280 285 Thr Cys Ala Lys Cys Pro Pro His Ser Tyr Ser Val Trp Glu Gly Ala 290 295 300 Thr Ser Cys Thr Cys Asp Arg Gly Phe Phe Arg Ala Asp Asn Asp Ala 305 310 315 320 Ala Ser Met Pro Cys Thr Arg Pro Pro Ser Ala Pro Leu Asn Leu He 325 330 335 Ser Asn Val Asn Glu Thr Ser Val Asn Leu Glu Trp Ser Ser Pro Gin 340 345 350 Asn Thr Gly Gly Arg Gin Asp He Ser Tyr Asn Val Val Cys Lys Lys 355 360 365 Cys Gly Ala Gly Asp Pro Ser Lys Cys Arg Pro Cys Gly Ser Gly Val 370 375 380 His Tyr Thr Pro Gin Gin Asn Gly Leu Lys Thr Thr Lys Val Ser He 385 390 395 400 Thr Asp Leu Leu Ala His Thr Asn Tyr Thr Phe Glu He Trp Ala Val 405 410 415 Asn Gly Val Ser Lys Tyr Asn Pro Asn Pro Asp Gin Ser Val Ser Val 420 425 430 Thr Val Thr Thr Asn Gin Ala Ala Pro Ser Ser He Ala Leu Val Gin 435 440 445 Ala Lys Glu Val Thr Arg Tyr Ser Val Ala Leu Ala Trp Leu Glu Pro 450 455 460 Asp Arg Pro Asn Gly Val He Leu Glu Tyr Glu Val Lys Tyr Tyr Glu 465 470 475 480 Lys Asp Gin Asn Glu Arg Ser Tyr Arg He Val Arg Thr Ala Ala Arg 485 490 495 Asn Thr Asp He Lys Gly Leu Asn Pro Leu Thr Ser Tyr Val Phe His 500 505 510 Val Arg Ala Arg Thr Ala Ala Gly Tyr Gly Asp Phe Ser Glu Pro Leu 515 520 525 Glu Val Thr Thr Asn Thr Val Pro Ser Arg He He Gly Asp Gly Ala 530 535 540 Asn Ser Thr Val Leu Leu Val Ser Val Ser Gly Ser Val Val Leu Val 545 550 555 560 Val He Leu He Ala Ala Phe Val He Ser Arg Arg Arg Ser Lys Tyr 565 570 575 Ser Lys Ala Lys Gin Glu Ala Asp Glu Glu Lys His Leu Asn Gin Gly 580 585 590 Val Arg Thr Tyr Val Asp Pro Phe Thr Tyr Glu Asp Pro Asn Gin Ala 595 600 605 Val Arg Glu Phe Ala Lys Glu He Asp Ala Ser Cys He Lys He Glu 610 615 620 Lys Val He Gly Val Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu 625 630 635 640 Lys Val Pro Gly Lys Arg Glu He Cys Val Ala He Lys Thr Leu Lys 645 650 655 Ala Gly Tyr Thr Asp Lys Gin Arg Arg Asp Phe Leu Ser Glu Ala Ser 660 665 670 He Met Gly Gin Phe Asp His Pro Asn He He His Leu Glu Gly Val 675 680 685 Val Thr Lys Cys Lys Pro Val Met He He Thr Glu Tyr Met Glu Asn 690 695 700 Gly Ser Leu Asp Ala Phe Leu Arg Lys Asn Asp Gly Arg Phe Thr Val 705 710 715 720 He Gin Leu Val Gly Met Leu Arg Gly He Gly Ser Gly Met Lys Tyr 725 730 735 Leu Ser Asp Met Ser Tyr Val His Arg Asp Leu Ala Ala Arg Asn He 740 745 750 Leu Val Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Met Ser 755 760 765 Arg Val Leu Glu Asp Asp Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly 770 775 780 Lys He Pro He Arg Trp Thr Ala Pro Glu Ala He Ala Tyr Arg Lys 785 790 795 800 Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Met Trp Glu 805 810 815 Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gin Asp 820 825 830 Val He Lys Ala He Glu Glu Gly Tyr Arg Leu Pro Pro Pro Met Asp 835 840 845 Cys Pro He Ala Leu His Gin Leu Met Leu Asp Cys Trp Gin Lys Glu 850 855 860 Arg Ser Asp Arg Pro Lys Phe Gly Gin He Val Asn Met Leu Asp Lys 865 870 875 880 Leu He Arg Asn Pro Asn Ser Leu Lys Arg Thr Gly Thr Glu Ser Ser 885 890 895 Arg Pro Asn Thr Ala Leu Leu Asp Pro Ser Ser Pro Glu Phe Ser Ala 900 905 910 Val Val Ser Val Gly Asp Trp Leu Gin Ala He Lys Met Asp Arg Tyr 915 920 925 Lys Asp Asn Phe Thr Ala Ala Gly Tyr Thr Thr Leu Glu Ala Val Val 930 935 940 His Val Asn Gin Glu Asp Leu Ala Arg He Gly He Thr Ala He Thr 945 950 955 960 His Gin Asn Lys He Leu Ser Ser Val Gin Ala Met Arg Thr Gin Met 965 970 975 Gin Gin Met His Gly Arg Met Val Pro Val 980 985 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4529 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 186..3182 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: CGGTGCGAGC GAACAGGAGT GGGGGGGAAA TTAAAAAAAG CTAAACGTGG AGCAGCCGAT 60 CGGGGACCGA GAAGGGGAAT CGATGCAAGG AGCACACTAA AACAAAAGCT ACTTCGGAAC 120 AAACAGCATT TAAAAATCCA CGACTCAAGA TAACTGAAAC CTAAAATAAA ACCTGCTCAT 180 GCACC ATG GTT TTT CAA ACT CGG TAC CCT TCA TGG ATT ATT TTA TGC 227 Met Val Phe Gin Thr Arg Tyr Pro Ser Trp He He Leu Cys 1 5 10 TAC ATC TGG CTG CTC CGC TTT GCA CAC ACA GGG GAG GCG CAG GCT GCG 275 Tyr He Trp Leu Leu Arg Phe Ala His Thr Gly Glu Ala Gin Ala Ala 15 20 25 30 AAG GAA GTA CTA CTG CTG GAT TCT AAA GCA CAA CAA ACA GAG TTG GAG 323 Lys Glu Val Leu Leu Leu Asp Ser Lys Ala Gin Gin Thr Glu Leu Glu 35 40 45 TGG ATT TCC TCT CCA CCC AAT GGG TGG GAA GAA ATT AGT GGT TTG GAT 371 Trp He Ser Ser Pro Pro Asn Gly Trp Glu Glu He Ser Gly Leu Asp 50 55 60 GAG AAC TAT ACC CCG ATA CGA ACA TAC CAG GTG TGC CAA GTC ATG GAG 419 Glu Asn Tyr Thr Pro He Arg Thr Tyr Gin Val Cys Gin Val Met Glu 65 70 75 CCC AAC CAA AAC AAC TGG CTG CGG ACT AAC TGG ATT TCC AAA GGC AAT 467 Pro Asn Gin Asn Asn Trp Leu Arg Thr Asn Trp He Ser Lys Gly Asn 80 85 90 GCA CAA AGG ATT TTT GTA GAA TTG AAA TTC ACC CTG AGG GAT TGT AAC 515 Ala Gin Arg He Phe Val Glu Leu Lys Phe Thr Leu Arg Asp Cys Asn 95 100 105 110 AGT CTT CCT GGA GTA CTG GGA ACT TGC AAG GAA ACA TTT AAT TTG TAC 563 Ser Leu Pro Gly Val Leu Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr 115 120 125 TAT TAT GAA ACA GAC TAT GAC ACT GGC AGG AAT ATA AGA GAA AAC CTC 611 Tyr Tyr Glu Thr Asp Tyr Asp Thr Gly Arg Asn He Arg Glu Asn Leu 130 135 140 TAT GTA AAA ATA GAC ACC ATT GCT GCA GAT GAA AGT TTT ACC CAA GGT 659 Tyr Val Lys He Asp Thr He Ala Ala Asp Glu Ser Phe Thr Gin Gly 145 150 155 GAC CTT GGT GAA AGA AAG ATG AAG CTT AAC ACT GAG GTG AGA GAG ATT 707 Asp Leu Gly Glu Arg Lys Met Lys Leu Asn Thr Glu Val Arg Glu He 160 165 170 GGA CCT TTG TCC AAA AAG GGA TTC TAT CTT GCC TTT CAG GAT GTA GGG 755 Gly Pro Leu Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gin Asp Val Gly 175 180 185 190 GCT TGC ATA GCT TTG GTT TCT GTC AAA GTG TAC TAC AAG AAG TGC TGG 803 Ala Cys He Ala Leu Val Ser Val Lys Val Tyr Tyr Lys Lys Cys Trp 195 200 205 TCC ATT ATT GAG AAC TTA GCT ATC TTT CCA GAT ACA GTG ACT GGT TCA 851 Ser He He Glu Asn Leu Ala He Phe Pro Asp Thr Val Thr Gly Ser 210 215 220 GAA TTT TCC TCT TTA GTC GAG GTT CGA GGG ACA TGT GTC AGC AGT GCA 899 Glu Phe Ser Ser Leu Val Glu Val Arg Gly Thr Cys Val Ser Ser Ala 225 230 235 GAG GAA GAA GCG GAA AAC GCC CCC AGG ATG CAC TGC AGT GCA GAA GGA 947 Glu Glu Glu Ala Glu Asn Ala Pro Arg Met His Cys Ser Ala Glu Gly 240 245 250 GAA TGG TTA GTG CCC ATT GGA AAA TGT ATC TGC AAA GCA GGC TAC CAG 995 Glu Trp Leu Val Pro He Gly Lys Cys He Cys Lys Ala Gly Tyr Gin 255 260 265 270 CAA AAA GGA GAC ACT TGT GAA CCC TGT GGC CGT GGG TTC TAC AAG TCT 1043 Gin Lys Gly Asp Thr Cys Glu Pro Cys Gly Arg Gly Phe Tyr Lys Ser 275 280 285 TCC TCT CAA GAT CTT CAG TGC TCT CGT TGT CCA ACT CAC AGT TTT TCT 1091 Ser Ser Gin Asp Leu Gin Cys Ser Arg Cys Pro Thr His Ser Phe Ser 290 295 300 GAT AAA GAA GGC TCC TCC AGA TGT GAA TGT GAA GAT GGG TAT TAC AGG 1139 Asp Lys Glu Gly Ser Ser Arg Cys Glu Cys Glu Asp Gly Tyr Tyr Arg 305 310 315 GCT CCA TCT GAC CCA CCA TAC GTT GCA TGC ACA AGG CCT CCA TCT GCA 1187 Ala Pro Ser Asp Pro Pro Tyr Val Ala Cys Thr Arg Pro Pro Ser Ala 320 325 330 CCA CAG AAC CTC ATT TTC AAC ATC AAC CAA ACC ACA GTA AGT TTG GAA 1235 Pro Gin Asn Leu He Phe Asn He Asn Gin Thr Thr Val Ser Leu Glu 335 340 345 350 TGG AGT CCT CCT GCA GAC AAT GGG GGA AGA AAC GAT GTG ACC TAC AGA 1283 Trp Ser Pro Pro Ala Asp Asn Gly Gly Arg Asn Asp Val Thr Tyr Arg 355 360 365 ATA TTG TGT AAG CGG TGC AGT TGG GAG CAG GGC GAA TGT GTT CCC TGT 1331 He Leu Cys Lys Arg Cys Ser Trp Glu Gin Gly Glu Cys Val Pro Cys 370 375 380 GGG AGT AAC ATT GGA TAC ATG CCC CAG CAG ACT GGA TTA GAG GAT AAC 1379 Gly Ser Asn He Gly Tyr Met Pro Gin Gin Thr Gly Leu Glu Asp Asn 385 390 395 TAT GTC ACT GTC ATG GAC CTG CTA GCC CAC GCT AAT TAT ACT TTT GAA 1427 Tyr Val Thr Val Met Asp Leu Leu Ala His Ala Asn Tyr Thr Phe Glu 400 405 410 GTT GAA GCT GTA AAT GGA GTT TCT GAC TTA AGC CGA TCC CAG AGG CTC 1475 Val Glu Ala Val Asn Gly Val Ser Asp Leu Ser Arg Ser Gin Arg Leu 415 420 425 430 TTT GCT GCT GTC AGT ATC ACC ACT GGT CAA GCA GCT CCC TCG CAA GTG 1523 Phe Ala Ala Val Ser He Thr Thr Gly Gin Ala Ala Pro Ser Gin Val 435 440 445 AGC GGA GTA ATG AAG GAG AGA GTA CTG CAG CGG AGT GTC GAG CTT TCC 1571 Ser Gly Val Met Lys Glu Arg Val Leu Gin Arg Ser Val Glu Leu Ser 450 455 460 TGG CAG GAA CCA GAG CAT CCC AAT GGA GTC ATC ACA GAA TAT GAA ATC 1619 Trp Gin Glu Pro Glu His Pro Asn Gly Val He Thr Glu Tyr Glu He 465 470 475 AAG TAT TAC GAG AAA GAT CAA AGG GAA CGG ACC TAC TCA ACA GTA AAA 1667 Lys Tyr Tyr Glu Lys Asp Gin Arg Glu Arg Thr Tyr Ser Thr Val Lys 480 485 490 ACC AAG TCT ACT TCA GCC TCC ATT AAT AAT CTG AAA CCA GGA ACA GTG 1715 Thr Lys Ser Thr Ser Ala Ser He Asn Asn Leu Lys Pro Gly Thr Val 495 500 505 510 TAT GTT TTC CAG ATT CGG GCT TTT ACT GCT GCT GGT TAT GGA AAT TAC 1763 Tyr Val Phe Gin He Arg Ala Phe Thr Ala Ala Gly Tyr Gly Asn Tyr 515 520 525 AGT CCC AGA CTT GAT GTT GCT ACA CTA GAG GAA GCT ACA GGT AAA ATG 1811 Ser Pro Arg Leu Asp Val Ala Thr Leu Glu Glu Ala Thr Gly Lys Met 530 535 540 TTT GAA GCT ACA GCT GTC TCC AGT GAA CAG AAT CCT GTT ATT ATC ATT 1859 Phe Glu Ala Thr Ala Val Ser Ser Glu Gin Asn Pro Val He He He 545 550 555 GCT GTG GTT GCT GTA GCT GGG ACC ATC ATT TTG GTG TTC ATG GTC TTT 1907 Ala Val Val Ala Val Ala Gly Thr He He Leu Val Phe Met Val Phe 560 565 570 GGC TTC ATC ATT GGG AGA AGG CAC TGT GGT TAT AGC AAA GCT GAC CAA 1955 Gly Phe He He Gly Arg Arg His Cys Gly Tyr Ser Lys Ala Asp Gin 575 580 585 590 GAA GGC GAT GAA GAG CTT TAC TTT CAT TTT AAA TTT CCA GGC ACC AAA 2003 Glu Gly Asp Glu Glu Leu Tyr Phe His Phe Lys Phe Pro Gly Thr Lys 595 600 605 ACC TAC ATT GAC CCT GAA ACC TAT GAG GAC CCA AAT AGA GCT GTC CAT 2051 Thr Tyr He Asp Pro Glu Thr Tyr Glu Asp Pro Asn Arg Ala Val His 610 615 620 CAA TTC GCC AAG GAG CTA GAT GCC TCC TGT ATT AAA ATT GAG CGT GTG 2099 Gin Phe Ala Lys Glu Leu Asp Ala Ser Cys He Lys He Glu Arg Val 625 630 635 ATT GGT GCA GGA GAA TTC GGT GAA GTC TGC AGT GGC CGT TTG AAA CTT 2147 He Gly Ala Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu Lys Leu 640 645 650 CCA GGG AAA AGA GAT GTT GCA GTA GCC ATA AAA ACC CTG AAA GTT GGT 2195 Pro Gly Lys Arg Asp Val Ala Val Ala He Lys Thr Leu Lys Val Gly 655 660 665 670 TAC ACA GAA AAA CAA AGG AGA GAC TTT TTG TGT GAA GCA AGC ATC ATG 2243 Tyr Thr Glu Lys Gin Arg Arg Asp Phe Leu Cys Glu Ala Ser He Met 675 680 685 GGG CAG TTT GAC CAC CCA AAT GTT GTC CAT TTG GAA GGG GTT GTT ACA 2291 Gly Gin Phe Asp His Pro Asn Val Val His Leu Glu Gly Val Val Thr 690 695 700 AGA GGG AAA CCA GTC ATG ATA GTA ATA GAG TTC ATG GAA AAT GGA GCC 2339 Arg Gly Lys Pro Val Met He Val He Glu Phe Met Glu Asn Gly Ala 705 710 715 CTA GAT GCA TTT CTC AGG AAA CAT GAT GGG CAA TTT ACA GTC ATT CAG 2387 Leu Asp Ala Phe Leu Arg Lys His Asp Gly Gin Phe Thr Val He Gin 720 725 730 TTA GTA GGA ATG CTG AGA GGA ATT GCT GCT GGA ATG AGA TAT TTG GCT 2435 Leu Val Gly Met Leu Arg Gly He Ala Ala Gly Met Arg Tyr Leu Ala 735 740 745 750 GAT ATG GGA TAT GTT CAC AGG GAC CTT GCA GCT CGC AAT ATT CTT GTC 2483 Asp Met Gly Tyr Val His Arg Asp Leu Ala Ala Arg Asn He Leu Val 755 760 765 AAC AGC AAT CTC GTT TGT AAA GTG TCA GAT TTT GGC CTG TCC CGA GTT 2531 Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Val 770 775 780 ATA GAG GAT GAT CCA GAA GCT GTC TAT ACA ACT ACT GGT GGA AAA ATT 2579 He Glu Asp Asp Pro Glu Ala Val Tyr Thr Thr Thr Gly Gly Lys He 785 790 795 CCA GTA AGG TGG ACA GCA CCC GAA GCC ATC CAG TAC CGG AAA TTC ACA 2627 Pro Val Arg Trp Thr Ala Pro Glu Ala He Gin Tyr Arg Lys Phe Thr 800 805 810 TCA GCC AGT GAT GTA TGG AGC TAT GGA ATA GTC ATG TGG GAA GTT ATG 2675 Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Met Trp Glu Val Met 815 820 825 830 TCT TAT GGA GAA AGA CCT TAT TGG GAC ATG TCA AAT CAA GAT GTT ATA 2723 Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gin Asp Val He 835 840 845 AAA GCA ATA GAΛ GAA GGT TAT CGT TTA CCA GCA CCC ATG GAC TGC CCA 2771 Lys Ala He Glu Glu Gly Tyr Arg Leu Pro Ala Pro Met Asp Cys Pro 850 855 860 GCT GGC CTT CAC CAG CTA ATG TTG GAT TGT TGG CAA AAG GAG CGT GCT 2819 Ala Gly Leu His Gin Leu Met Leu Asp Cys Trp Gin Lys Glu Arg Ala 865 870 875 GAA AGG CCA AAA TTT GAA CAG ATA GTT GGA ATT CTA GAC AAA ATG ATT 2867 Glu Arg Pro Lys Phe Glu Gin He Val Gly He Leu Asp Lys Met He 880 885 890 CGA AAC CCA AAT AGT CTG AAA ACT CCC CTG GGA ACT TGT AGT AGG CCA 2915 Arg Asn Pro Asn Ser Leu Lys Thr Pro Leu Gly Thr Cys Ser Arg Pro 895 900 905 910 ATA AGC CCT CTT CTG GAT CAA AAC ACT CCT GAT TTC ACT ACC TTT TGT 2963 He Ser Pro Leu Leu Asp Gin Asn Thr Pro Asp Phe Thr Thr Phe Cys 915 920 925 TCA GTT GGA GAA TGG CTA CAA GCT ATT AAG ATG GAA AGA TAT AAA GAT 3011 Ser Val Gly Glu Trp Leu Gin Ala He Lys Met Glu Arg Tyr Lys Asp 930 935 940 AAT TTC ACG GCA GCT GGC TAC AAT TCC CTT GAA TCA GTA GCC AGG ATG 3059 Asn Phe Thr Ala Ala Gly Tyr Asn Ser Leu Glu Ser Val Ala Arg Met 945 950 955 ACT ATT GAG GAT GTG ATG AGT TTA GGG ATC ACA CTG GTT GGT CAT CAA 3107 Thr He Glu Asp Val Met Ser Leu Gly He Thr Leu Val Gly His Gin 960 965 970 AAG AAA ATC ATG AGC AGC ATT CAG ACT ATG AGA GCA CAA ATG CTA CAT 3155 Lys Lys He Met Ser Ser He Gin Thr Met Arg Ala Gin Met Leu His 975 980 985 990 TTA CAT GGA ACT GGC ATT CAA GTG TGATATGCAT TTCTCCCTTT TAAGGGAGAT 3209 Leu His Gly Thr Gly He Gin Val 995 TACAGACTGC AAGAGAACAG TACTGGCCTT CAGTATATGC ATAGAATGCT GCTAGAAGAC 3269 AAGTGATGTC CTGGGTCCTT CCAACAGTGA AGAGAAGATT TAAGAAGCAC CTATAGACTT 3329 GAACTCCTAA GTGCCACCAG AATATATAAA AAGGGAATTT AGGATCCACC ATCGGTGGCC 3389 AGGAAAATAG CAGTGACAAT AAACAAAGTA CTACCTGAAA AACATCCAAA CACCTTGAGC 3449 TCTCTAACCT CCTTTTTGTC TTATAGACTT TTTAAAATGT ACATAAAGAA TTTAAGAAAG 3509 AATATATTTG TCAAATAAAA TCATGATCTT ATTGTTAAAA TTAATGAAAT ATTTTCCTTA 3569 AATATGTGAT TTCAGACTAT TCCTTTTTAA AATCATTTGT GTTTATTCTT CATAAGGACT 3629 TTGTTTTAGA AAGCTGTTTA TAGCTTTGGA CCTTTTTAGT GTTAAATCTG TAACATTACT 3689 ACACTGGGTA CCTTTGAAAG AATCTCAAAT TTCAAAAGAA ATAGCATGAT TGAAGATACA 3749 TCTCTGTTAG AACATTGGTA TCCTTTTTGT GCCATTTTAT TCTGTTTAAT CAGTGCTGTT 3809 TTGATATTGT TTGCTAATTG GCAGGTAGTC AAGAAAATGC AAGTTGCCAA GAGCTCTGAT 3869 ATTTTTTAAA AAGAATTTTT TTGTAAAGAT CAGACAACAC ACTATCTTTT CAATGAAAAA 3929 AGCAATAATG ATCCATACAT ACTATAAGGC ACTTTTAACA GATTGTTTAT AGAGTGATTT 3989 TACTAGAAAG AATTTAATAA ACTCGAAGTT TAGGTTTATG AGTATATAAA CAAATGAGGC 4049 ACTTCATCTG AAGAATGTTG GTGAAGGCAA GTCTCTGAAA GCAGAACTAT CCAGTGTTAT 4109 CTAAAAATTA ATCTGAGCAC ATCAAGATTT TTTCATTCTC GTGACATTAG GAAATTTAGG 4169 ATAAATAGTT GACATATATT TTATATCCTC TTCTGTTGAA TGCAGTCCAA ACATGAAAGG 4229 AAATAATTGT TTTATATTAT AACTCTGAAG CATGATAAAG GGGCAGTTCA CAATTTTCAC 4289 CATTTAAACA CAAATTTGCT GCACAGAATA TCACCATTGC AGTTCAAAAC AAAACAAAAC 4349 AAAAAGTCTT TTGTTTGTGA ACACTGATGC AAGAAACTTG TTAAATGAAA GGACTCTTTA 4409 CCCTAGAAGG AAGAGGTGAA GGATCTGGCT TGTTTTTAAA GCTTTATTTA TTAAACCATA 4469 TTATTTGATT ACTGTGTTAG AATTTCATAA GCAATAATTA AATGTGTCTT TATGGAATTC 4529 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 998 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Val Phe Gin Thr Arg Tyr Pro Ser Trp He He Leu Cys Tyr He 1 5 10 15 Trp Leu Leu Arg Phe Ala His Thr Gly Glu Ala Gin Ala Ala Lys Glu 20 25 30 Val Leu Leu Leu Asp Ser Lys Ala Gin Gin Thr Glu Leu Glu Trp He 35 40 45 Ser Ser Pro Pro Asn Gly Trp Glu Glu He Ser Gly Leu Asp Glu Asn 50 55 60 Tyr Thr Pro He Arg Thr Tyr Gin Val Cys Gin Val Met Glu Pro Asn 65 70 75 80 Gin Asn Asn Trp Leu Arg Thr Asn Trp He Ser Lys Gly Asn Ala Gin 85 90 95 Arg He Phe Val Glu Leu Lys Phe Thr Leu Arg Asp Cys Asn Ser Leu 100 105 110 Pro Gly Val Leu Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Tyr 115 120 125 Glu Thr Asp Tyr Asp Thr Gly Arg Asn He Arg Glu Asn Leu Tyr Val 130 135 140 Lys He Asp Thr He Ala Ala Asp Glu Ser Phe Thr Gin Gly Asp Leu 145 150 155 160 Gly Glu Arg Lys Met Lys Leu Asn Thr Glu Val Arg Glu He Gly Pro 165 170 175 Leu Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gin Asp Val Gly Ala Cys 180 185 190 He Ala Leu Val Ser Val Lys Val Tyr Tyr Lys Lys Cys Trp Ser He 195 200 205 He Glu Asn Leu Ala He Phe Pro Asp Thr Val Thr Gly Ser Glu Phe 210 215 220 Ser Ser Leu Val Glu Val Arg Gly Thr Cys Val Ser Ser Ala Glu Glu 225 230 235 240 Glu Ala Glu Asn Ala Pro Arg Met His Cys Ser Ala Glu Gly Glu Trp 245 250 255 Leu Val Pro He Gly Lys Cys He Cys Lys Ala Gly Tyr Gin Gin Lys 260 265 270 Gly Asp Thr Cys Glu Pro Cys Gly Arg Gly Phe Tyr Lys Ser Ser Ser 275 280 285 Gin Asp Leu Gin Cys Ser Arg Cys Pro Thr His Ser Phe Ser Asp Lys 290 295 300 Glu Gly Ser Ser Arg Cys Glu Cys Glu Asp Gly Tyr Tyr Arg Ala Pro 305 310 315 320 Ser Asp Pro Pro Tyr Val Ala Cys Thr Arg Pro Pro Ser Ala Pro Gin 325 330 335 Asn Leu He Phe Asn He Asn Gin Thr Thr Val Ser Leu Glu Trp Ser 340 345 350 Pro Pro Ala Asp Asn Gly Gly Arg Asn Asp Val Thr Tyr Arg He Leu 355 360 365 Cys Lys Arg Cys Ser Trp Glu Gin Gly Glu Cys Val Pro Cys Gly Ser 370 375 380 Asn He Gly Tyr Met Pro Gin Gin Thr Gly Leu Glu Asp Asn Tyr Val 385 390 ' 395 400 Thr Val Met Asp Leu Leu Ala His Ala Asn Tyr Thr Phe Glu Val Glu 405 410 415 Ala Val Asn Gly Val Ser Asp Leu Ser Arg Ser Gin Arg Leu Phe Ala 420 425 430 Ala Val Ser He Thr Thr Gly Gin Ala Ala Pro Ser Gin Val Ser Gly 435 440 445 Val Met Lys Glu Arg Val Leu Gin Arg Ser Val Glu Leu Ser Trp Gin 450 455 460 Glu Pro Glu His Pro Asn Gly Val He Thr Glu Tyr Glu He Lys Tyr 465 470 475 480 Tyr Glu Lys Asp Gin Arg Glu Arg Thr Tyr Ser Thr Val Lys Thr Lys 485 490 495 Ser Thr Ser Ala Ser He Asn Asn Leu Lys Pro Gly Thr Val Tyr Val 500 505 510 Phe Gin He Arg Ala Phe Thr Ala Ala Gly Tyr Gly Asn Tyr Ser Pro 515 520 525 Arg Leu Asp Val Ala Thr Leu Glu Glu Ala Thr Gly Lys Met Phe Glu 530 535 , 540 Ala Thr Ala Val Ser Ser Glu Gin Asn Pro Val He He He Ala Val 545 550 555 560 Val Ala Val Ala Gly Thr He He Leu Val Phe Met Val Phe Gly Phe 565 570 575 He He Gly Arg Arg His Cys Gly Tyr Ser Lys Ala Asp Gin Glu Gly 580 585 590 Asp Glu Glu Leu Tyr Phe His Phe Lys Phe Pro Gly Thr Lys Thr Tyr 595 600 605 He Asp Pro Glu Thr Tyr Glu Asp Pro Asn Arg Ala Val His Gin Phe 610 615 620 Ala Lys Glu Leu Asp Ala Ser Cys He Lys He Glu Arg Val He Gly 625 630 635 640 Ala Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu Lys Leu Pro Gly 645 650 655 Lys Arg Asp Val Ala Val Ala He Lys Thr Leu Lys Val Gly Tyr Thr 660 665 670 Glu Lys Gin Arg Arg Asp Phe Leu Cys Glu Ala Ser He Met Gly Gin 675 680 685 Phe Asp His Pro Asn Val Val His Leu Glu Gly Val Val Thr Arg Gly 690 695 700 Lys Pro Val Met He Val He Glu Phe Met Glu Asn Gly Ala Leu Asp 705 710 715 720 Ala Phe Leu Arg Lys His Asp Gly Gin Phe Thr Val He Gin Leu Val 725 730 735 Gly Met Leu Arg Gly He Ala Ala Gly Met Arg Tyr Leu Ala Asp Met 740 745 750 Gly Tyr Val His Arg Asp Leu Ala Ala Arg Asn He Leu Val Asn Ser 755 760 765 Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Val He Glu 770 775 780 Asp Asp Pro Glu Ala Val Tyr Thr Thr Thr Gly Gly Lys He Pro Val 785 790 795 800 Arg Trp Thr Ala Pro Glu Ala He Gin Tyr Arg Lys Phe Thr Ser Ala 805 810 815 Ser Asp Val Trp Ser Tyr Gly He Val Met Trp Glu Val Met Ser Tyr 820 825 830 Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gin Asp Val He Lys Ala 835 840 845 He Glu Glu Gly Tyr Arg Leu Pro Ala Pro Met Asp Cys Pro Ala Gly 850 855 860 Leu His Gin Leu Met Leu Asp Cys Trp Gin Lys Glu Arg Ala Glu Arg 865 870 875 880 Pro Lys Phe Glu Gin He Val Gly He Leu Asp Lys Met He Arg Asn 885 890 895 Pro Asn Ser Leu Lys Thr Pro Leu Gly Thr Cys Ser Arg Pro He Ser 900 905 910 Pro Leu Leu Asp Gin Asn Thr Pro Asp Phe Thr Thr Phe Cys Ser Val 915 920 925 Gly Glu Trp Leu Gin Ala He Lys Met Glu Arg Tyr Lys Asp Asn Phe 930 935 940 Thr Ala Ala Gly Tyr Asn Ser Leu Glu Ser Val Ala Arg Met Thr He 945 950 955 960 Glu Asp Val Met Ser Leu Gly He Thr Leu Val Gly His Gin Lys Lys 965 970 975 He Met Ser Ser He Gin Thr Met Arg Ala Gin Met Leu His Leu His 980 985 990 Gly Thr Gly He Gin Val 995 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 976 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Met Glu Leu Gin Ala Ala Arg Ala Cys Phe Ala Leu Leu Trp Gly Cys 1 5 10 15 Ala Leu Ala Ala Ala Ala Ala Ala Gin Gly Lys Glu Val Val Leu Leu 20 25 30 Asp Phe Ala Ala Ala Gly Gly Glu Leu Gly Trp Leu Thr His Pro Tyr 35 40 45 Gly Lys Gly Trp Asp Leu Met Gin Asn He Met Asn Asp Met Pro He 50 55 60 Tyr Met Tyr Ser Val Cys Asn Val Met Ser Gly Asp Gin Asp Asn Trp 65 70 75 80 Leu Arg Thr Asn Trp Val Tyr Arg Gly Glu Ala Glu Arg Asn Asn Phe 85 90 95 Glu Leu Asn Phe Thr Val Arg Asp Cys Asn Ser Phe Pro Gly Gly Ala 100 105 110 Ser Ser Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Ala Glu Ser Asp Leu 115 120 125 Asp Tyr Gly Thr Asn Phe Gin Lys Arg Leu Phe Thr Lys He Asp Thr 130 135 140 He Ala Pro Asp Glu He Thr Val Ser Ser Asp Phe Glu Ala Arg His 145 150 155 160 Val Lys Leu Asn Val Glu Glu Arg Ser Val Gly Pro Leu Thr Arg Lys 165 170 175 Gly Phe Tyr Leu Ala Phe Gin Asp He Gly Ala Cys Val Ala Leu Leu 180 185 190 Ser Val Arg Val Tyr Tyr Lys Lys Cys Pro Glu Leu Leu Gin Gly Leu 195 200 205 Ala His Phe Pro Glu Thr He Ala Gly Ser Asp Ala Pro Ser Leu Ala 210 215 220 Thr Val Ala Gly Thr Cys Val Asp His Ala Val Val Pro Pro Gly Gly 225 230 235 240 Glu Glu Pro Arg Met His Cys Ala Val Asp Gly Glu Trp Leu Val Pro 245 250 255 He Gly Gin Cys Leu Cys Gin Ala Gly Tyr Glu Lys Val Glu Asp Ala 260 265 270 Cys Gin Ala Cys Ser Pro Gly Phe Phe Lys Phe Glu Ala Ser Glu Ser 275 280 285 Pro Cys Leu Glu Cys Pro Glu His Thr Leu Pro Ser Pro Glu Gly Ala 290 295 300 Thr Ser Cys Glu Cys Glu Glu Gly Phe Phe Arg Ala Pro Gin Asp Pro 305 310 315 320 Ala Ser Met Pro Cys Thr Arg Pro Pro Ser Ala Pro His Tyr Leu Thr 325 330 335 Ala Val Gly Met Gly Ala Lys Val Glu Leu Arg Trp Thr Pro Pro Gin 340 345 350 Asp Ser Gly Gly Arg Glu Asp He Val Tyr Ser Val Thr Cys Glu Gin 355 360 365 Cys Trp Pro Glu Ser Gly Glu Cys Gly Pro Cys Glu Ala Ser Val Arg 370 375 380 Tyr Ser Glu Pro Pro His Gly Leu Thr Arg Thr Ser Val Thr Val Ser 385 390 395 400 Asp Leu Glu Pro His Met Asn Tyr Thr Phe Thr Val Glu Ala Arg Asn 405 410 415 Gly Val Ser Gly Leu Val Thr Ser Arg Ser Phe Arg Thr Ala Ser Val 420 425 430 Ser He Asn Gin Thr Glu Pro Pro Lys Val Arg Leu Glu Gly Arg Ser 435 440 445 Thr Thr Ser Leu Ser Val Ser Trp Ser He Pro Pro Pro Gin Gin Ser 450 455 460 Arg Val Trp Lys Tyr Glu Val Thr Tyr Arg Lys Lys Gly Asp Ser Asn 465 470 475 480 Ser Tyr Asn Val Arg Arg Thr Glu Gly Phe Ser Val Thr Leu Asp Asp 485 490 495 Leu Ala Pro Asp Thr Thr Tyr Leu Val Gin Val Gin Ala Leu Thr Gin 500 505 510 Glu Gly Gin Gly Ala Gly Ser Lys Val His Glu Phe Gin Thr Leu Ser 515 520 525 Pro Glu Gly Ser Gly Asn Leu Ala Val He Gly Gly Val Ala Val Gly 530 535 540 Val Val Leu Leu Leu Val Leu Ala Gly Val Gly Phe Phe He His Arg 545 550 555 560 Arg Arg Lys Asn Gin Arg Ala Arg Gin Ser Pro Glu Asp Val Tyr Phe 565 570 575 Ser Lys Ser Glu Gin Leu Lys Pro Leu Lys Thr Tyr Val Asp Pro His 580 585 590 Thr Tyr Glu Asp Pro Asn Gin Ala Val Leu Lys Phe Thr Thr Glu He 595 600 605 His Pro Ser Cys Val Thr Arg Gin Lys Val He Gly Ala Gly Glu Phe 610 615 620 Gly Glu Val Tyr Lys Gly Met Leu Lys Thr Ser Ser Gly Lys Lys Glu 625 630 635 640 Val Pro Val Ala He Lys Thr Leu Lys Ala Gly Tyr Thr Glu Lys Gin 645 650 655 Arg Val Asp Phe Leu Gly Glu Ala Gly He Met Gly Gin Phe Ser His 660 665 670 His Asn He He Arg Leu Glu Gly Val He Ser Lys Tyr Lys Pro Met 675 680 685 Met He He Thr Glu Tyr Met Glu Asn Gly Ala Leu Asp Lys Phe Leu 690 695 700 Arg Glu Lys Asp Gly Glu Phe Ser Val Leu Gin Leu Val Gly Met Leu 705 710 715 720 Arg Gly He Ala Ala Gly Met Lys Tyr Leu Ala Asn Met Asn Tyr Val 725 730 735 His Arg Asp Leu Ala Ala Arg Asn He Leu Val Asn Ser Asn Leu Val 740 745 750 Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Val Leu Glu Asp Asp Pro 755 760 765 Glu Ala Thr Tyr Thr Thr Ser Gly Gly Lys He Pro He Arg Trp Thr 770 775 780 Ala Pro Glu Ala He Ser Tyr Arg Lys Phe Thr Ser Ala Ser Asp Val 785 790 795 800 Trp Ser Phe Gly He Val Met Trp Glu Val Met Thr Tyr Gly Glu Arg 805 810 815 Pro Tyr Trp Glu Leu Ser Asn His Glu Val Met Lys Ala He Asn Asp 820 825 830 Gly Phe Arg Leu Pro Thr Pro Met Asp Cys Pro Ser Ala He Tyr Gin 835 840 845 Leu Met Met Gin Cys Trp Gin Gin Glu Arg Ala Arg Arg Pro Lys Phe 850 855 860 Ala Asp He Val Ser He Leu Asp Lys Leu He Arg Ala Pro Asp Ser 865 870 875 880 Leu Lys Thr Leu Ala Asp Phe Asp Pro Arg Val Ser He Arg Leu Pro 885 890 895 Ser Thr Ser Gly Ser Glu Gly Val Pro Phe Arg Thr Val Ser Glu Trp 900 905 910 Leu Glu Ser He Lys Met Gin Gin Tyr Thr Glu His Phe Met Ala Ala 915 920 925 Gly Tyr Thr Ala He Glu Lys Val Val Gin Met Thr Asn Asp Asp He 930 935 940 Lys Arg He Gly Val Arg Leu Pro Gly His Gin Lys Arg He Ala Tyr 945 950 955 960 Ser Leu Leu Gly Leu Lys Asp Gin Val Asn Thr Val Gly He Pro He 965 970 975 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 984 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Glu Arg Arg Trp Pro Leu Gly Leu Gly Leu Val Leu Leu Leu Cys 1 5 10 15 Ala Pro Leu Pro Pro Gly Ala Arg Ala Lys Glu Val Thr Leu Met Asp 20 25 30 Thr Ser Lys Ala Gin Gly Glu Leu Gly Trp Leu Leu Asp Pro Pro Lys 35 40 45 Asp Gly Trp Ser Glu Gin Gin Gin He Leu Asn Gly Thr Pro Leu Tyr 50 55 60 Met Tyr Gin Asp Cys Pro Met Gin Gly Arg Arg Asp Thr Asp His Trp 65 70 75 80 Leu Arg Ser Asn Trp He Tyr Arg Gly Glu Glu Ala Ser Arg Val His 85 90 95 Val Glu Leu Gin Phe Thr Val Arg Asp Cys Lys Ser Phe Pro Gly Gly 100 105 110 Ala Gly Pro Leu Gly Cys Lys Glu Thr Phe Asn Leu Leu Tyr Met Glu 115 120 125 Ser Asp Gin Asp Val Gly He Gin Leu Arg Arg Pro Leu Phe Gin Lys 130 135 140 Val Thr Thr Val Ala Ala Asp Gin Ser Phe Thr He Arg Asp Leu Ala 145 150 155 160 Ser Gly Ser Val Lys Leu Asn Val Glu Arg Cys Ser Leu Gly Arg Leu 165 170 175 Thr Arg Arg Gly Leu Tyr Leu Ala Phe His Asn Pro Gly Ala Cys Val 180 185 190 Ala Leu Val Ser Val Arg Val Phe Tyr Gin Arg Cys Pro Glu Thr Leu 195 200 205 Asn Gly Leu Ala Gin Phe Pro Asp Thr Leu Pro Gly Pro Ala Gly Leu 210 215 220 Val Glu Val Ala Gly Thr Cys Leu Pro His Ala Arg Ala Ser Pro Arg 225 230 235 240 Pro Ser Gly Ala Pro Arg Met His Cys Ser Pro Asp Gly Glu Trp Leu 245 250 255 Val Pro Val Gly Arg Cys His Cys Glu Pro Gly Tyr Glu Glu Gly Gly 260 265 270 Ser Gly Glu Ala Cys Val Ala Cys Pro Ser Gly Ser Tyr Arg Met Asp 275 280 285 Met Asp Thr Pro His Cys Leu Thr Cys Pro Gin Gin Ser Thr Ala Glu 290 295 300 Ser Glu Gly Ala Thr He Cys Thr Cys Glu Ser Gly His Tyr Arg Ala 305 310 315 320 Pro Gly Glu Gly Pro Gin Val Ala Cys Thr Gly Pro Pro Ser Ala Pro 325 330 335 Arg Asn Leu Ser Phe Ser Ala Ser Gly Thr Gin Leu Ser Leu Arg Trp 340 345 350 Glu Pro Pro Ala Asp Thr Gly Gly Arg Gin Asp Val Arg Tyr Ser Val 355 360 365 Arg Cys Ser Gin Cys Gin Gly Thr Ala Gin Asp Gly Gly Pro Cys Gin 370 375 380 Pro Cys Gly Val Gly Val His Phe Ser Pro Gly Ala Arg Ala Leu Thr 385 390 395 400 Thr Pro Ala Val His Val Asn Gly Leu Glu Pro Tyr Ala Asn Tyr Thr 405 410 415 Phe Asn Val Glu Ala Gin Asn Gly Val Ser Gly Leu Gly Ser Ser Gly 420 425 430 His Ala Ser Thr Ser Val Ser He Ser Met Gly His Ala Glu Ser Leu 435 440 445 Ser Gly Leu Ser Leu Arg Leu Val Lys Lys Glu Pro Arg Gin Leu Glu 450 455 460 Leu Thr Trp Ala Gly Ser Arg Pro Arg Ser Pro Gly Ala Asn Leu Thr 465 470 475 480 Tyr Glu Leu His Val Leu Asn Gin Asp Glu Glu Arg Tyr Gin Met Val 485 490 495 Leu Glu Pro Arg Val Leu Leu Thr Glu Leu Gin Pro Asp Thr Thr Tyr 500 505 510 He Val Arg Val Arg Met Leu Thr Pro Leu Gly Pro Gly Pro Phe Ser 515 520 525 Pro Asp His Glu Phe Arg Thr Ser Pro Pro Val Ser Arg Gly Leu Thr 530 535 540 Gly Gly Glu He Val Ala Val He Phe Gly Leu Leu Leu Gly Ala Ala 545 550 555 560 Leu Leu Leu Gly He Leu Val Phe Arg Ser Arg Arg Ala Gin Arg Gin 565 570 575 Arg Gin Gin Arg His Val Thr Ala Pro Pro Met Trp He Glu Arg Thr 580 585 590 Ser Cys Ala Glu Ala Leu Cys Gly Thr Ser Arg His Thr Arg Thr Leu 595 600 605 His Arg Glu Pro Trp Thr Leu Pro Gly Gly Trp Ser Asn Phe Pro Ser 610 615 620 Arg Glu Leu Asp Pro Ala Trp Leu Met Val Asp Thr Val He Gly Glu 625 630 635 640 Gly Glu Phe Gly Glu Val Tyr Arg Gly Thr Leu Arg Leu Pro Ser Gin 645 650 655 Asp Cys Lys Thr Val Ala He Lys Thr Leu Lys Asp Thr Ser Pro Gly 660 665 670 Gly Gin Trp Trp Asn Phe Leu Arg Glu Ala Thr He Met Gly Gin Phe 675 680 685 Ser His Pro His He Leu His Leu Glu Gly Val Val Thr Lys Arg Lys 690 695 700 Pro He Met He He Thr Glu Phe Met Glu Asn Ala Ala Leu Asp Ala 705 710 715 720 Phe Leu Arg Glu Arg Glu Asp Gin Leu Val Pro Gly Gin Leu Val Ala 725 730 735 Met Leu Gin Gly He Ala Ser Gly Met Asn Tyr Leu Ser Asn His Asn 740 745 750 Tyr Val His Arg Asp Leu Ala Ala Arg Asn He Leu Val Asn Gin Asn 755 760 765 Leu Cys Cys Lys Val Ser Asp Phe Gly Leu Thr Arg Leu Leu Asp Asp 770 775 780 Phe Asp Gly Thr Tyr Glu Thr Gin Gly Gly Lys He Pro He Arg Trp 785 790 795 800 Thr Ala Pro Glu Ala He Ala His Arg He Phe Thr Thr Ala Ser Asp 805 810 815 Val Trp Ser Phe Gly He Val Met Trp Glu Val Leu Ser Phe Gly Asp 820 825 830 Lys Pro Tyr Gly Glu Met Ser Asn Gin Glu Val Met Lys Ser He Glu 835 840 845 Asp Gly Tyr Arg Leu Pro Pro Pro Val Asp Cys Pro Ala Pro Leu Tyr 850 855 860 Glu Leu Met Lys Asn Cys Trp Ala Tyr Asp Arg Ala Arg Arg Pro His 865 870 875 880 Phe Gin Lys Leu Gin Ala His Leu Glu Gin Leu Leu Ala Asn Pro His 885 890 895 Ser Leu Arg Thr He Ala Asn Phe Asp Pro Arg Val Thr Leu Arg Leu 900 905 910 Pro Ser Leu Ser Gly Ser Asp Gly He Pro Tyr Arg Thr Val Ser Glu 915 920 925 Trp Leu Glu Ser He Arg Met Lys Arg Tyr He Leu His Phe His Ser 930 935 940 Ala Gly Leu Asp Thr Met Glu Cys Val Leu Glu Leu Thr Ala Glu Asp 945 950 955 960 Leu Thr Gin Met Gly He Thr Leu Pro Gly His Gin Lys Arg He Leu 965 970 975 Cys Ser He Gin Gly Phe Lys Asp 980 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 998 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Met Ala Arg Ala Arg Pro Pro Pro Pro Pro Ser Pro Pro Pro Gly Leu 1 5 10 15 Leu Pro Leu Leu Pro Pro Leu Leu Leu Leu Pro Leu Leu Leu Leu Pro 20 25 30 Ala Gly Cys Arg Ala Leu Glu Glu Thr Leu Met Asp Thr Lys Trp Val 35 40 45 Thr Ser Glu Leu Ala Trp Thr Ser His Pro Glu Ser Gly Trp Glu Glu 50 55 60 Val Ser Gly Tyr Asp Glu Ala Met Asn Pro He Arg Thr Tyr Gin Val 65 70 75 80 Cys Asn Val Arg Glu Ser Ser Gin Asn Asn Trp Leu Arg Thr Gly Phe 85 90 95 He Trp Arg Arg Asp Val Gin Arg Val Tyr Val Glu Leu Lys Phe Thr 100 105 110 Val Arg Asp Cys Asn Ser He Pro Asn He Pro Gly Ser Cys Lys Glu 115 120 125 Thr Phe Asn Leu Phe Tyr Tyr Glu Ala Asp Ser Asp Val Ala Ser Ala 130 135 140 Ser Ser Pro Phe Trp Met Glu Asn Pro Tyr Val Lys Val Asp Thr He 145 150 155 160 Ala Pro Asp Glu Ser Phe Ser Arg Leu Asp Ala Gly Arg Val Asn Thr 165 170 175 Lys Val Arg Ser Phe Gly Pro Leu Ser Lys Ala Gly Phe Tyr Leu Ala 180 185 190 Phe Gin Asp Gin Gly Ala Cys Met Ser Leu He Ser Val Arg Ala Phe 195 200 205 Tyr Lys Lys Cys Ala Ser Thr Thr Ala Gly Phe Ala Leu Phe Pro Glu , 210 215 220 Thr Leu Thr Gly Ala Glu Pro Thr Ser Leu Val He Ala Pro Gly Thr 225 230 235 240 Cys He Pro Asn Ala Val Glu Val Ser Val Pro Leu Lys Leu Tyr Cys 245 250 255 Asn Gly Asp Gly Glu Trp Met Val Pro Val Gly Ala Cys Thr Cys Ala 260 265 270 Thr Gly His Glu Pro Ala Ala Lys Glu Ser Gin Cys Arg Pro Cys Pro 275 280 285 Pro Gly Ser Tyr Lys Ala Lys Gin Gly Glu Gly Pro Cys Leu Pro Cys 290 295 300 Pro Pro Asn Ser Arg Thr Thr Ser Pro Ala Ala Ser He Cys Thr Cys 305 310 315 320 His Asn Asn Phe Tyr Arg Ala Asp Ser Asp Ser Ala Asp Ser Ala Cys 325 330 335 Thr Thr Val Pro Ser Pro Pro Arg Gly Val He Ser Asn Val Asn Glu 340 345 350 Thr Ser Leu He Leu Glu Trp Ser Glu Pro Arg Asp Leu Gly Val Arg 355 360 365 Asp Asp Leu Leu Tyr Asn Val He Cys Lys Lys Cys His Gly Ala Gly 370 375 380 Gly Ala Ser Ala Cys Ser Arg Cys Asp Asp Asn Val Glu Phe Val Pro 385 390 395 400 Arg Gin Leu Gly Leu Ser Glu Pro Arg Val His Thr Ser His Leu Leu 405 410 415 Ala His Thr Arg Tyr Thr Phe Glu Val Gin Ala Val Asn Gly Val Ser 420 425 430 Gly Lys Ser Pro Leu Pro Pro Arg Tyr Ala Ala Val Asn He Thr Thr 435 440 445 Asn Gin Ala Ala Pro Ser Glu Val Pro Thr Leu Arg Leu His Ser Ser 450 455 460 Ser Gly Ser Ser Leu Thr Leu Ser Trp Ala Pro Pro Glu Arg Pro Asn 465 470 475 480 Gly Val He Leu Asp Tyr Glu Met Lys Tyr Phe Glu Lys Ser Glu Gly 485 490 495 He Ala Ser Thr Val Thr Ser Gin Met Asn Ser Val Gin Leu Asp Gly 500 505 510 Leu Arg Pro Asp Ala Arg Tyr Val Val Gin Val Arg Ala Arg Thr Val 515 520 525 Ala Gly Tyr Gly Gin Tyr Ser Arg Pro Ala Glu Phe Glu Thr Thr Ser 530 535 540 Glu Arg Gly Ser Gly Ala Gin Gin Leu Gin Glu Gin Leu Pro Leu He 545 550 555 560 Val Gly Ser Ala Thr Ala Gly Leu Val Phe Val Val Ala Val Val Val 565 570 575 He Ala He Val Cys Leu Arg Lys Gin Arg His Gly Ser Asp Ser Glu 580 585 590 Tyr Thr Glu Lys Leu Gin Gin Tyr He Ala Pro Gly Met Lys Val Tyr 595 600 605 He Asp Pro Phe Thr Tyr Glu Asp Pro Asn Glu Ala Val Arg Glu Phe 610 615 620 Ala Lys Glu He Asp Val Ser Cys Val Lys He Glu Glu Val He Gly 625 630 635 640 Ala Gly Glu Phe Gly Glu Val Cys Arg Gly Arg Leu Lys Gin Pro Gly 645 650 655 Arg Arg Glu Val Phe Val Ala He Lys Thr Leu Lys Val Gly Tyr Thr 660 665 670 Glu Arg Gin Arg Arg Asp Phe Leu Ser Glu Ala Ser He Met Gly Gin 675 680 685 Phe Asp His Pro Asn He He Arg Leu Glu Gly Val Val Thr Lys Ser 690 695 700 Arg Pro Val Met He Leu Thr Glu Phe Met Glu Asn Cys Ala Leu Asp 705 710 715 720 Ser Phe Leu Arg Leu Asn Asp Gly Gin Phe Thr Val He Gin Leu Val 725 730 735 Gly Met Leu Arg Gly He Ala Ala Gly Met Lys Tyr Leu Ser Glu Met 740 745 750 Asn Tyr Val His Arg Asp Leu Ala Ala Arg Asn He Leu Val Asn Ser 755 760 765 Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser Arg Phe Leu Glu 770 775 780 Asp Asp Pro Ser Asp Pro Thr Tyr Thr Ser Ser Leu Gly Gly Lys He 785 790 795 800 Pro He Arg Trp Thr Ala Pro Glu Ala He Ala Tyr Arg Lys Phe Thr 805 810 815 Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Met Trp Glu Val Met 820 825 830 Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gin Asp Val He 835 840 845 Asn Ala Val Glu Gin Asp Tyr Arg Leu Pro Pro Pro Met Asp Cys Pro 850 855 860 Thr Ala Leu His Gin Leu Met Leu Asp Cys Trp Val Arg Asp Arg Asn 865 870 875 880 Leu Arg Pro Lys Phe Ser Gin He Val Asn Thr Leu Asp Lys Leu He 885 890 895 Arg Asn Ala Ala Ser Leu Lys Val He Ala Ser Ala Gin Ser Gly Met 900 905 910 Ser Gin Pro Leu Leu Asp Arg Thr Val Pro Asp Tyr Thr Thr Phe Thr 915 920 925 Thr Val Gly Asp Trp Leu Asp Ala He Lys Met Gly Arg Tyr Lys Glu 930 935 940 Ser Phe Val Ser Ala Gly Phe Ala Ser Phe Asp Leu Val Ala Gin Met 945 950 955 960 Thr Ala Glu Asp Leu Leu Arg He Gly Val Thr Leu Ala Gly His Gin 965 970 975 Lys Lys He Leu Ser Ser He Gin Asp Met Arg Leu Gin Met Asn Gin 980 985 990 Thr Leu Pro Val Gin Val 995 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 983 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Met Asp Cys Gin Leu Ser He Leu Leu Leu Leu Ser Cys Ser Val Leu 1 5 10 15 - 86 - Asp Ser Phe Gly Glu Leu He Pro Gin Pro Ser Asn Glu Val Asn Leu 20 25 30 Leu Asp Ser Lys Thr He Gin Gly Glu Leu Gly Trp He Ser Tyr Pro 35 40 45 Ser His Gly Trp Glu Glu He Ser Gly Val Asp Glu His Tyr Thr Pro 50 55 60 He Arg Thr Tyr Gin Val Cys Asn Val Met Asp His Ser Gin Asn Asn 65 70 75 80 Trp Leu Arg Thr Asn Trp Val Pro Arg Asn Ser Ala Gin Lys He Tyr 85 90 95 Val Glu Leu Lys Phe Thr Leu Arg Asp Cys Asn Ser He Pro Leu Val 100 105 110 Leu Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Met Glu Ser Asp 115 120 125 Asp Asp His Gly Val Lys Phe Arg Glu His Gin Phe Thr Lys He Asp 130 135 140 Thr He Ala Ala Asp Glu Ser Phe Thr Gin Met Asp Leu Gly Asp Arg 145 150 155 160 He Leu Lys Leu Asn Thr Glu He Arg Glu Val Gly Pro Val Asn Lys 165 170 175 Lys Gly Phe Tyr Leu Ala Phe Gin Asp Val Gly Ala Cys Val Ala Leu 180 185 190 Val Ser Val Arg Val Tyr Phe Lys Lys Cys Pro Phe Thr Val Lys Asn 195 200 205 Leu Ala Met Phe Pro Asp Thr Val Pro Met Asp Ser Gin Ser Leu Val 210 215 220 Glu Val Arg Gly Ser Cys Val Asn Asn Ser Lys Glu Glu Asp Pro Pro 225 230 235 240 Arg Met Tyr Cys Ser Thr Glu Gly Glu Trp Leu Val Pro He Gly Lys 245 250 255 Cys Ser Cys Asn Ala Gly Tyr Glu Glu Arg Gly Phe Met Cys Gin Ala 260 265 270 Cys Arg Pro Gly Phe Tyr Lys Ala Leu Asp Gly Asn Met Lys Cys Ala 275 280 285 Lys Cys Pro Pro His Ser Ser Thr Gin Glu Asp Gly Ser Met Asn Cys 290 295 300 Arg Cys Glu Asn Asn Tyr Phe Arg Ala Asp Lys Asp Pro Pro Ser Met 305 310 315 320 Ala Cys Thr Arg Pro Pro Ser Ser Pro Arg Asn Val He Ser Asn He 325 330 335 Asn Glu Thr Ser Val He Leu Asp Trp Ser Trp Pro Leu Asp Thr Gly 340 345 350 Gly Arg Lys Asp Val Thr Phe Asn He He Cys Lys Lys Cys Gly Trp 355 360 365 Asn He Lys Gin Cys Glu Pro Cys Ser Pro Asn Val Arg Phe Leu Pro 370 375 380 Arg Gin Phe Gly Leu Thr Asn Thr Thr Val Thr Val Thr Asp Leu Leu 385 390 395 400 Ala His Thr Asn Tyr Thr Phe Glu He Asp Ala Val Asn Gly Val Ser 405 410 415 Glu Leu Ser Ser Pro Pro Arg Gin Phe Ala Ala Val Ser He Thr Thr 420 425 430 Asn Gin Ala Ala Pro Ser Pro Val Leu Thr He Lys Lys Asp Arg Thr 435 440 445 Ser Arg Asn Ser He Ser Leu Ser Trp Gin Glu Pro Glu His Pro Asn 450 455 460 Gly He He Leu Asp Tyr Glu Val Lys Tyr Tyr Glu Lys Gin Glu Gin 465 470 475 480 Glu Thr Ser Tyr Thr He Leu Arg Ala Arg Gly Thr Asn Val Thr He 485 490 495 Ser Ser Leu Lys Pro Asp Thr He Tyr Val Leu Gin He Arg Ala Arg 500 505 510 Thr Ala Ala Gly Tyr Gly Thr Asn Ser Arg Lys Phe Glu Phe Glu Thr 515 520 525 Ser Pro Asp Ser Phe Ser He Ser Gly Glu Ser Ser Gin Val Val Met 530 535 540 He Ala He Ser Ala Ala Val Ala He He Leu Leu Thr Val Val He 545 550 555 560 Tyr Val Leu He Gly Arg Phe Cys Gly Tyr Lys Ser Lys His Gly Ala 565 570 575 Asp Glu Lys Arg Leu His Phe Gly Asn Gly His Leu Lys Leu Pro Gly 580 585 590 Leu Arg Thr Tyr Val Asp Pro His Thr Tyr Glu Asp Pro Thr Gin Ala 595 600 605 Val His Glu Phe Ala Lys Glu Leu Asp Ala Thr Asn He Ser He Asp 610 615 620 Lys Val Val Gly Ala Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu 625 630 635 640 Lys Leu Pro Ser Lys Lys Glu He Ser Val Ala He Lys Thr Leu Lys 645 650 655 Val Gly Tyr Thr Glu Lys Gin Arg Arg Asp Phe Leu Gly Glu Ala Ser 660 665 670 He Met Gly Gin Phe Asp His Pro Asn He He Arg Leu Glu Gly Val 675 680 685 Val Thr Lys Ser Lys Pro Val Met He Val Thr Glu Tyr Met Glu Asn 690 695 700 Gly Ser Leu Asp Ser Phe Leu Arg Lys His Asp Ala Gin Phe Thr Val 705 710 715 720 He Gin Leu Val Gly Met Leu Arg Gly He Ala Ser Gly Met Lys Tyr 725 730 735 Leu Ser Asp Met Gly Tyr Val His Arg Asp Leu Ala Ala Arg Asn He 740 745 750 Leu He Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Leu Ser 755 760 765 Arg Val Leu Glu Asp Asp Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly 770 775 780 Lys He Pro He Arg Trp Thr Ser Pro Glu Ala He Ala Tyr Arg Lys 785 790 795 800 Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly He Val Leu Trp Glu 805 810 815 Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Glu Met Ser Asn Gin Asp 820 825 830 Val He Lys Ala Val Asp Glu Gly Tyr Arg Leu Pro Pro Pro Met Asp 835 840 845 Cys Pro Ala Ala Leu Tyr Gin Leu Met Leu Asp Cys Trp Gin Lys Asp 850 855 860 Arg Asn Asn Arg Pro Lys Phe Glu Gin He Val Ser He Leu Asp Lys 865 870 875 880 Leu He Arg Asn Pro Gly Ser Leu Lys He He Thr Ser Ala Ala Ala 885 890 895 Arg Pro Ser Asn Leu Leu Leu Asp Gin Ser Asn Val Asp He Ser Thr 900 905 910 Phe Arg Thr Thr Gly Asp Trp Leu Asn Gly Val Arg Thr Ala His Cys 915 920 925 Lys Glu He Phe Thr Gly Val Glu Tyr Ser Ser Cys Asp Thr He Ala 930 935 940 Lys He Ser Thr Asp Asp Met Lys Lys Val Gly Val Thr Val Val Gly 945 950 955 960 Pro Gin Lys Lys He He Ser Ser He Lys Ala Leu Glu Thr Gin Ser 965 970 975 Lys Asn Gly Pro Val Pro Val 980 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: CTGCTCGCCG CCGTGGAAGA AACG 24 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GCGTCTAGAT TATCACTTCT CCTGGATGCT TGTCTGGTA 39 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GCGGACGCCG CCGCCATGGC CCTGGATTGC CTGCTGCTGT TCCTCCTG 48 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: CGTTTCTTCC ACGGCGGCGA GCAGAGATGC CAGGAGGAAC AGCAGCAGGC AATC 54 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Ala Leu Asp Cys Leu Leu Leu Phe Leu Leu Ala Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AGGGAATTCC AYCGNGAYYT NGCNGC 26 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: AGGGGATCCR WARS CCANA CRTC 24

Claims: WHAT IS CLAIMED IS: 1. An isolated nucleic acid encoding a polypeptide having at least one of the biological activities of an EPH-like receptor protein tyrosine kinase, the nucleic acid selected from the group consisting of: (a) the nucleic acids set forth in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16 and their complementary strands; (b) a nucleic acid hybridizing to the coding regions of the nucleic acids in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16; and (c) a nucleic acid of (b) which, but for the degeneracy of the genetic code, would hybridize to the coding regions of the nucleic acids in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16. 2. A polypeptide product of expression of a nucleic acid of Claim 1 in a procaryotic or eucaryotic host cell. 3. A nucleic acid of Claim 1 which is of human origin. 4. A nucleic acid of Claim 1 which encodes a polypeptide having part or all of the amino acid sequence as shown in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16. 5. A nucleic acid of Claim 1 encoding a fragment comprising an EPH-like receptor extracellular domain. 6. A nucleic acid of Claim 1 which is cDNA, genomic DNA, synthetic DNA or RNA. 7. A nucleic acid of Claim 1 which includes one or more codons preferred for expression in E. coli host cells. 8. A nucleic acid of Claim 1 which includes one or more codon preferred for expression in mammalian cells. 9. A nucleic acid encoding amino acids 6-524 as set forth in SEQ ID NO: 10, and optionally encoding an amino terminal methionyl residue. 10. A nucleic acid encoding amino acids 1-547 as set forth in SEQ ID NO: 12, and optionally encoding an amino acid terminal methionyl residue. 11. A nucleic acid encoding amino acids 21- 547 as set forth in SEQ ID NO: 14, and optionally encoding an amino terminal methionyl residue. 12. A nucleic acid encoding amino acids 23- 553 as set forth in SEQ ID NO: 16, and optionally encoding an amino terminal methionyl residue. 13. A nucleic acid encoding a chimeric protein, wherein the protein comprises an EPH-like receptor extracellular domain fused to a heterologous receptor cytoplasmic domain. 14. A nucleic acid of Claim 13 wherein the extracellular domain is selected from the group consisting of HEK5, HEK7, HEK8 and HEKll extracellular domains. 15. A biologically functional plasmid or viral DNA vector including a nucleic acid of Claim 1. 16. A procaryotic or eucaryotic host cell stably transformed or transfected with the plasmid of Claim 15. 17. A method of producing an EPH-like receptor protein tyrosine kinase comprising culturing the host cell of Claim 16 to allow the host cell to express the EPH-like receptor protein tyrosine kinase. 18. An isolated polypeptide having an amino acid sequence as shown in any of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14 or SEQ ID NO: 16, or a fragment or analog thereof, wherein the polypeptide has at least one of the biological activities of an EPH-like receptor protein tyrosine kinase. 19. Purified and isolated HEK5 receptor. 20. Purified and isolated HEK7 receptor. 21. Purified and isolated HEK8 receptor. 22. Purified and isolated HEKll receptor. 23. A polypeptide of Claim 18 wherein the biological activity is the binding of a ligand. 24. A polypeptide of Claim 18 which is of human origin. 25. A polypeptide of Claims 18 characterized by being the product of procaryotic or eucaryotic expression of an exogenous DNA sequence. 26. A polypeptide of Claim 25 wherein the exogenous DNA is a cDNA. 27. A polypeptide of Claim 25 wherein the exogenous DNA is a genomic DNA. 28. An antibody or fragment thereof specifically binding a polypeptide of Claim 18. 29. An antibody of Claim 28 which is a monoclonal antibody. 30. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide of Claim 18 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer or diluent. 31. A pharmaceutical composition comprising a therapeutically effective amount of an antibody of Claim 28 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer or diluent. 32. A method for modulating the endogenous activation of an EPH-like receptor protein tyrosine kinase comprising administering an effective amount of a polypeptide of Claim 18. 33. A method for modulating the synthesis of an EPH-like receptor protein tyrosine kinase comprising hybridizing an antisense oligonucleotide to a nucleic acid of Claim 1. 34. A method of identifying a ligand that binds to a receptor polypeptide of Claim 18 comprising the steps of: a) exposing at least one molecule to the receptor polypeptide for a time sufficient to allow formation of a receptor/ligand complex; b) removing non-complexed molecules; and c) detecting the presence of the molecule bound to the receptor polypeptide.

Inventors: FOX GARY M, JING SHUQIAN, WELCHER ANDREW A, FOX, GARY, M., JING, SHUQIAN, WELCHER, ANDREW, A.
Applicants: AMGEN INC, AMGEN INC.
Application year: 1995
Main classification: C12N15
IPC codes: A01K67, A61K31, A61K38, A61K39, A61K48, A61P1, A61P25, A61P43, C07H21, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1, G01N33